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Drosophila models for human diseases have helped in advancing 
our knowledge on human diseases and the discovery of potential 
treatments. Angelman syndrome is a rare neurological disorder that 
results in severe mental retardation and loss of motor coordination. The 
disease is caused by loss-of-function mutations in the UBE3A gene 
encoding a HECT domain ubiquitin protein ligase. Drosophila dube3a is 
the fly homolog of human UBE3A and their protein products share ~55% 
similarity in amino acid sequence along the entire length of the proteins. 
My goal was to develop a Drosophila AS model that will allow us to 
identify the AS-associated substrate(s) of the Drosophila UBE3A 
homolog and ultimately, to determine why the lack of UBE3A protein 
causes Angelman syndrome in humans. Dube3a is present in the 
embryonic, larval and adult central nervous system, including the adult 
mushroom bodies, which is the center for learning and memory. I have 
generated dube3a knock-out flies and they appear normal externally, but 
 vii
display abnormal locomotor behaviors. Flies that overexpress wild-type 
dube3a in the nervous system also display locomotion defects, and 
these overexpression phenotypes are dependent on the presence of a 
conserved cysteine residue essential for HECT domain E3 enzymatic 
activity. Targeted overexpression of dube3a in the eye, the wing, or 
ubiquitously causes rough eyes, curly wings and lethality, respectively. 
These morphological abnormalities in the eye or wing depend on the 
critical catalytic cysteine of Dube3a. Overexpression of mutant dube3a 
carrying AS-associated point mutations does not elicit such defects, 
suggesting they act as loss-of-function mutants. Taken together, dube3a 
mutants are a candidate fly model for Angelman syndrome, and the flies 
that overexpress dube3a in the eye or wing are useful for genetic 
screens to identify the elusive UBE3A substrates relevant to Angelman 
syndrome. 
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Chapter 1: General Introduction 
 
THE UBIQUITIN PATHWAY AND HUMAN DISEASES 
 
Ubiquitin is a 76 amino acid long globular polypeptide, highly 
conserved from yeast to humans. Covalent attachment of ubiquitin 
molecules to target proteins provides a dynamic and reversible 
posttranslational regulation of protein functions. Ubiquitination has been 
implicated in a variety of cellular processes, such as transcription 
regulation, cell-cycle control, cell signaling, apoptosis, DNA replication 
and damage repair, immune response, and protein subcellular 
localization (Weissman 2001). Malfunctions of the ubiquitin pathway play 
roles in many human diseases, including neurodegenerative diseases, 
cancers, and metabolic disorders (Sakamoto 2002; Miller and Wilson 
2003). Ubiquitination modifies protein functions in two ways. First, 
certain poly-ubiquitin chains direct tagged proteins to the proteasome, a 
multi-subunit proteolytic complex, for degradation. Second, mono-
ubiquitination and a subset of polyubiquitin linkages modulate protein 
functions in ways reminiscent of phosphorylation (Hicke 2001). 
 
The Ubiquitin Conjugating System 
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Protein ubiquitination occurs through a series of enzymatic 
reactions usually composed of a ubiquitin-activating enzyme (E1), a 
ubiquitin-conjugating enzyme or ubiquitin-carrier proteins (E2) and a 
ubiquitin-protein ligase (E3). Ubiquitin modification is a reversible 
process. Ubiquitin moieties attached to the target protein can be 
removed from the substrate, disassembled and recycled by 
deubiquitinating enzymes.  
 
Ubiquitin-activating enzyme (E1) 
Ubiquitin is initially activated by the E1 enzyme in an ATP-
dependent manner, resulting in thiolester bond formation between the 
carboxyl-terminal glycine of the ubiquitin molecule and a conserved 
cysteine residue in the E1 active site. In S. cerevisiae, the UBA1 gene 
encodes the 114 kDa Uba1p protein and is essential for yeast cell 
viability (McGrath et al. 1991). The human E1 enzyme exists in two 
isoforms, both of which are translated from the same mRNA through 
alternative translation initiation codons. The 117 kDa E1a isoform is 
phosphorylated, which regulates its nuclear versus cytoplasmic 
localization, in a manner that depends on the cell-cycle. The 110 kDa 
short isoform E1b is not phosphorylated and, in contrast to E1a, has a 
primarily cytoplasmic distribution. Although these two isoforms are 
indistinguishable in their E2 recruitment capabilities, their different 
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localization might provide a mechanism for selecting substrate proteins 
for ubiquitination (Handley et al. 1991; Handley-Gearhart et al. 1994; 
Stephen et al. 1996; Shang et al. 2001).  
 
Ubiquitin-conjugating enzyme (E2) 
The activated ubiquitin moiety is transferred form the E1 enzyme 
to an E2 enzyme by forming a thiolester bond between the ubiquitin 
carboxyl-end glycine and a cysteine in the E2 active site. All E2s share a 
~150 amino acid UBC domain containing the conserved cysteine. The 
E2s can be assigned into four structural classes: class-I E2s consist 
almost exclusively of the core domain only; class-II E2s have additional 
carboxyl-terminal sequences; class-III E2s have amino-terminal 
extensions and class-IV E2s have both amino- and carboxyl end 
extensions (Plafker et al. 2004). The amino- and/or carboxyl- extended 
segments might promote interactions with the upstream E1, downstream 
E3 or even the final substrates (Pickart 2001; Weissman 2001). Although 
ubiquitin target specificity is thought to depend mainly on E3s (see 
below), the variety of E2s apparently confers substrate recognition and 
selection to a certain extent.  A single E2 can work with several but not 
all E3s, and a single E3 can interact with many but not all E2s. Thus, the 
various permutations and combinations of E2-E3 complexes elicit a 
plethora of target protein specifications (Weissman 2001). Furthermore, 
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the observation that the transport receptor importin-11 binds to ubiquitin-
loaded class-III E2s, and shuttles them from the cytoplasm to the 
nucleus, grants an interesting new layer of ubiquitin pathway regulation 
(Plafker et al. 2004; Zhang and Matunis 2005).  
 
Ubiquitin protein ligases (E3) 
The spectrum of E3 ligases is much larger than that of E2 
enzymes and new members continue to be identified. In the enzymatic 
cascade of the ubiquitin pathway, the E3 ligase is the major determinant 
of substrate specificity. Identification of E3 substrate(s) will help in 
understanding the ubiquitin pathway and its mechanisms.  
 
There are two major classes of E3s: the HECT (Homologous to 
E6AP C-terminus) domain E3s and the RING (Really Interesting New 
Gene) domain E3s. Unlike RING E3s, which bring the E2 to the 
substrate and facilitate the direct transfer of the ubiquitin moiety from the 
E2 to the substrate, HECT domain E3s themselves receive the ubiquitin 
moiety from the upstream E2s and then pass it to the substrates. In the 
HECT domain, the carboxyl terminal ~350 amino acid sequence, a 
highly conserved cysteine residue located ~35 amino acids upstream of 
the C-terminus is the site for thiolester bond-mediated ubiquitin 




HECT domain E3s 
HECT domain E3s are modular enzymes, with the divergent 
amino termini responsible for substrate binding and thus defining target 
protein specificity, and the carboxyl terminal HECT domain for E2 
binding and catalytic ubiquitin transfer in the E2 E3 substrate order. 
However, as the HECT domains of different HECT enzymes cannot be 
interchanged, it is likely that HECT domain itself contributes, at least 
partially, to substrate specification (Rotin et al. 2000; Pickart 2001). 
 
The founder of the HECT domain E3 ligase family is E6AP (E6-
associated protein), a ~100 kDa cellular protein. E6AP is encoded by the 
UBE3A gene, and E6AP and UBE3A refer to the same protein product. 
E6AP was identified as the E3 that mediates tumor suppressor p53 
ubiquitination in cervical cancer cells infected by high-risk human 
papillomavirus HPV16 or HPV18 (Huibregtse et al. 1993; Scheffner et al. 
1993). p53 is not an E6AP substrate in normal cells and the recognition 
of p53 as an E6AP substrate in HPV-infected cells requires the presence 
of the E6 viral protein. In a sense, E6 hijacks E6AP by changing its 
substrate specificity. Ubiquitination of p53 by the E6/E6AP complex 
leads to its proteasomal degradation. In E6AP, the high-risk E6 binding 
site is composed of 18 amino acids and located ~120 amino acids N-
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terminal to the HECT domain (see Figure 2.1) (Huibregtse et al. 1993). 
The association of E6 with E6AP is the prerequisite step for these two 
proteins to form a stable complex with p53. The ~240 amino acids long 
region immediately N-terminal to the HECT domain in E6AP, 
encompassing the E6 binding motif, is required for p53 binding 
(Huibregtse et al. 1993; Huibregtse and Beaudenon 1996). How these 
three proteins physically bind to each other in the p53/E6/E6AP ternary 
complex is still not clear. E6/E6AP complex also targets the ubiquitin-
mediated degradation of hDlg (the human homolog of Drosophila Disc 
large) (Matsumoto et al. 2006; Kuballa et al. 2007) and hScrib (the 
human homolog of Drosophila Scribble) (Nakagawa and Huibregtse 
2000). These proteins are tumor suppressor proteins as well and 
function in epithelial cell polarity regulation. Similar to p53, E6AP only 
targets the ubiquitination of hScrib and hDlg in the presence of E6.  
Through mediating the degradation of p53, hScrib and hDlg, E6AP plays 
an important role in high-risk E6-related carcinogenesis.  
 
Several proteins have been identified as potential constitutive 
E6AP substrates. HHR23A, a human homolog of the yeast DNA repair 
protein Rad23, is reported to be an E6-independent target of E6AP 
(Kumar et al. 1999). The interaction between E6AP and HHR23A is 
mediated by E6AP N-terminal region, while the E6AP HECT domain is 
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incapable of HHR23A binding. Several Src family tyrosine kinases, 
including Blk (B-lymphoid-specific tyrosine kinase) and Src itself, may 
also be ubiquitinated by E6AP and then subject to proteasome-mediated 
degradation (Oda et al. 1999). Another potential substrate of E6AP is the 
multicopy maintenance protein 7 (Mcm7), a subunit of the replication 
licensing factor (Kuhne and Banks 1998). The direct association of E6AP 
and Mcm7 is facilitated by the L2G domains present in both proteins 
(Kuhne and Banks 1998). The L2G domain in E6AP overlaps with the 
minimal E6-binding site in E6AP, with the L2G consensus sequence 
(S/TXXXLLG) located inside the E6-binding sequence (see Figure 2.1). 
E6AP also functions as its own substrate in vitro and this process may 
be promoted by E6 protein in HPV-infected cells (Nuber et al. 1998; Kao 
et al. 2000). The minimal region of E6AP required for serving as an 
E6AP substrate is ~570 amino acids long, with the C-terminal end ~100 
amino acids away from E6AP C-terminus (Nuber et al. 1998). These 
available data enforce the idea that the substrate specificity of E6AP is 
conferred by its N-terminal sequence. However, a common ubiquitination 
signal shared by all these E6-independent E6AP substrates remains 
elusive.  
 
In addition to E6AP, only a small portion of HECT domain proteins 
have been studied in detail about their catalytic activities as well as 
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substrate recognitions. The majority of such investigated HECT proteins 
belong to the Nedd4 (neural precursor cell-expressed developmentally 
downregulated gene 4) subclass HECT domain E3s. In addition to the 
carboxyl terminal HECT domain, the Nedd4-like proteins have a C2 
domain near the amino end and two to four WW domains at the middle 
of the protein. This Nedd4 subclass is conserved from yeast to human, 
with one Nedd4-like protein in S. cerevisiae, three in C. elegans and D. 
melanogaster, and more in human and mouse (Ingham et al. 2004; 
Shearwin-Whyatt et al. 2006).  
 
Originally identified in protein kinase C and later in various 
proteins, the C2 or calcium/ lipid binding domains are ~120 amino acids 
in length and can bind to calcium, phospholipids and other proteins in a 
calcium-dependent manner. The C2 domains play roles in membrane 
translocation and functional regulation of the Nedd4 proteins (Plant et al. 
1997; Ingham et al. 2004).  
 
WW domains are ~35 amino acids long protein-protein interaction 
domains with two conserved tryptophan residues ~20 amino acids apart 
(Harvey and Kumar 1999; Ingham et al. 2004). The WW domains in 
Nedd4 family E3s mediate the interaction between the substrate and the 
enzyme by binding to proline-rich motifs in the substrates, such as PPxY 
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and phosphorylated serine or threonine residues followed by a proline 
residue (Shearwin-Whyatt et al. 2006). In vitro, WW2 domains from 
different Nedd4 family members can bind to the same PY motifs and 
different WW domains from the same E3 have different binding 
specificity to the same substrate (Harvey and Kumar 1999).  As some of 
the targets of the Nedd4 family E3s don’t have apparent WW domain-
interacting modules, it was speculated that adaptor proteins carrying PY 
motifs can recruit the Nedd4 E3s to such atypical substrates (Harvey 
and Kumar 1999; Shearwin-Whyatt et al. 2006). 
 
The combination of multi-WW domains in Nedd4 family members 
and the variable protein-binding preference of different WW domains 
expand the range of cellular proteins that potentially can interact with 
Nedd4 family proteins, as well as the complexity of tuning Nedd4 family 
functions (Shearwin-Whyatt et al. 2006).  
 
In addition to the WW domains, the C2 domains of Nedd4-like 
proteins contribute to localizing the HECT domain proteins, through 
phospholipid-membrane targeting or binding to accessory protein 
positioning signals. This provides another level of Nedd4-substrate 
specificity by regulating the physical juxtaposition of the E3 enzyme and 




Nedd4 family proteins play roles in an array of cellular processes, 
including cell signaling, cellular transports, cell-cycle control and 
transcription regulation. Substrates of Nedd4 family proteins have 
diverse subcellular distributions and functions. Rsp5p is the only Nedd4-
like protein in S. cerevisiae and has divergent substrates involved in 
unrelated cellular processes, including the large subunits of RNA 
polymerase II, Gap1 (the general amino acid permease), Fur4p (the 
uracil permease) and Ste2p (the alpha factor receptor) (Rotin et al. 2000; 
Shearwin-Whyatt et al. 2006).  In vertebrates, the TGF-β (Transforming 
growth factor-β) signaling pathway is tightly controlled by the ubiquitin 
pathway with the Nedd4-like protein Smurf 1 (Smad ubiquitination-
related factor 1), Smurf2 and SCF/Roc1 as the major E3s (Izzi and 
Attisano 2004). Smurf1 and Smurf2 bind directly to Smad (Sma/Mad 
related proteins) through the WW-PY modules interaction, and mediate 
its ubiquitination and degradation. Smad also functions as an adaptor 
protein to bridge the interaction of Smurf1/2 to other components of the 
TGF-β pathway, such as the TGF-β receptor and transcription 
suppressor SnoN, thus leading to their degradation (Ingham et al. 2004; 
Shearwin-Whyatt et al. 2006). The renal epithelial sodium channel ENaC 
is the best-studied substrate of mammalian Nedd4-2 and regulates 
unidirectional flow of the sodium into epithelial cells. ENac is composed 
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by α, β and γ subunits carrying PY motifs at their carboxyl-termini. 
Nedd4-2 binds to ENaC through these PY motifs and mediates ENaC 
ubiquitination and internalization, thus downregulating the cell surface 
distribution of ENaC (Flores et al. 2003; Snyder 2005). 
 
RING finger domain E3s 
The size of the RING finger domain ubiquitin E3 family is much 
larger than the HECT domain ubiquitin ligase family. The RING finger 
domain is composed of forty to one hundred amino acids with the linear 
sequence Cys-X2-Cys-X9-39-Cys-X1-3-His-X2-3-Cys/His-X2-Cys-X4-48-Cys-
X2-Cys. The eight conserved cysteine and histidine residues coordinate 
two zinc ions in a “cross-brace” manner. The RING domain is the site for 
E2 binding. Other than the RING finger domains, the RING finger 
proteins have unrelated sequences (Freemont 2000; Fang et al. 2003).  
 
RING finger domain E3s can be categorized into simple RING 
E3s and complex RING E3s. For simple or single subunit RING domain 
E3s, such as Cbl (Casitas B-lineage lymphoma), BRCA1 (breast cancer 
specific tumor suppressor protein 1) and Mdm2 (Murine double minute 
2), the E2 binding and the substrate recognition capacities lie in a single 
protein. It is relatively common, however, for RING E3s to perform their 
enzymatic activity by forming homodimers or heterodimers through their 
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RING finger domains or other part of the proteins. For example, BRCA1 
forms a heterodimer with BARD1 (BRCA1 associated RING domain 1), 
which is a more stable and potent E3 than BRCA1 on its own. Similarly, 
the Mdm2-Mdm4 heterodimer makes a more effective E3 than Mdm2 
alone. For complex RING domain E3s, the ubiquitin ligase enzymatic 
activity is performed by a multisubunit protein complex, such as APC 
(the anaphase promoting complex) or cyclosome, VHL (the von-Hippel 
Lindau complex) and SCF (the Skp1-Culin1-F box complex). In these 
RING E3 complexes, there is one RING finger domain protein, one 
protein from the Cullin family, and some other proteins that may facilitate 
substrate interaction. Usually, the RING finger domain subunit recruits 
the E2, the Cullin protein acts as the scaffolding component and the 
other subunits are responsible for substrate binding and complex 
assembly (Hershko and Shapira 2006). Given that RING finger proteins 
lack apparent homology aside of the RING finger domains, no specific 
substrate interaction mode can be defined by RING finger E3s 
(Glickman and Ciechanover 2002; Fang et al. 2003; Lehner et al. 2005). 
 
Deubiquitinating enzymes (DUBs) 
Ubiquitination is a reversible process, as the ubiquitin moiety 
attached to the substrate can be removed or shortened by 
deubiquitinating enzymes (DUBs). DUBs can be divided into two groups 
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according to the catalytic mechanism of their protease activity: cysteine 
proteases and metalloproteases. All DUBs from the metalloprotease 
group carry the JAMM (Jab1/MPN/Mov34) protease motif. The cysteine 
protease DUBs can be further divided into four subclasses based on 
their catalytic domain structure: UCH (ubiquitin carboxyl-terminal 
hydrolase), USP (ubiquitin-specific protease), OUT (ovarian tumor 
protease) and MJD (Machado-Joseph disease protease). OUTs, MJDs 
and JAMM motif proteases are relatively recent members of the DUB 
family and their functions await further investigations (Amerik and 
Hochstrasser 2004; Nijman et al. 2005; Millard and Wood 2006). The 
first described DUBs are UCHs which have a preference for small 
ubiquitin-attached substrates and are involved mainly in ubiquitin 
recycling. UCHs also catalyze the processing of ubiquitin precursors 
translated as polyubiquitin chains or fused ubiquitin-ribosomal protein 
into singular ubiquitin molecules. USPs forms the largest and most 
diverse subclass of DUBs.  They release ubiquitin from large substrates 
and disassemble ubiquitin polymer chains (Weissman 2001; Amerik and 
Hochstrasser 2004; Nijman et al. 2005). 
 
Monoubiquitination versus polyubiquitination 
Ub-tagged target proteins take a variety of fates including 
degradation by the proteasome complex, targeting to certain subcellular 
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organelles, or alterations in their functions. The destiny of the 
ubiquitinated targets depends on  the number of ubiquitins conjugated 
onto the substrate, whether they are single ubiquitins or  chains, and if 
chains, the particular lysine residues of ubiquitin used to link the chain 
(Weissman 2001; Hoppe 2005).  
 
The ubiquitin system was first discovered by its ability to mark 
cellular proteins for proteasomal degradation. Proteasomal degradation 
usually requires that the substrate is conjugated with a polyubiquitin 
chain with at least four ubiquitins. Polyubiquitin chains are formed by 
attaching the carboxyl-terminal glycine of a ubiquitin monomer to an 
internal lysine residue of the previously incorporated ubiquitin. In the 
highly conserved ubiquitin molecule, there are seven internal lysine 
residues that potentially can be utilized for addition of another ubiquitin. 
They are Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63 and the most- 
studied ones are Lys11, Lys29, Lys48 and Lys63. Ubiquitin polymers built 
through Lys48 linkage usually serve as an efficient degradation tag and 
deliver the attached substrate to the 26S proteasomal complex, where 
the substrates are degraded into small peptides. This is a crucial 
process for the cell survival, as unwanted or misfolded proteins can be 
cleared away to ensure proper cellular functioning. Polyubiquitin chains 
formed with Lys63-linkages usually send target proteins to non-
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proteasomal pathways, such as cellular signaling, DNA damage repair, 
and transcription regulation, presumably through providing binding 
surfaces for proteins facilitating such processes. Lys29-linkage, Lys11-
linkage, Lys6-linkage are also used to generate polyubiquitin chains in 
vivo, although their physiological significances are still unclear (Fang and 
Weissman 2004; Starita and Parvin 2006; Willis and Patterson 2006). 
 
The ubiquitin pathway targets can be mono-ubiquitinated with a 
single ubiquitin attached to a substrate lysine residue, or multi-
ubiquitinated with multiple lysines of the substrate attached with a single 
ubiquitin moiety.  Mono- or multi-ubiquitination plays a role in modulating 
target protein activity and is involved in a variety of subcellular processes 
including endocytosis, protein trafficking, and DNA damage repair (Hicke 
2001; Hicke and Dunn 2003; Mukhopadhyay and Riezman 2007). 
 
Ubiquitination and Human Diseases 
The enormous number of cellular proteins subject to ubiquitin 
modification indicates the involvement of the ubiquitin pathway in almost 
every aspect of subcellular processes. It comes as no surprise that the 
ubiquitin pathway is interwoven in the pathogenesis of various human 
diseases, including neurodegenerative diseases, cardiovascular 
diseases, cancers and metabolic disorders to name just a few 
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(Sakamoto 2002; Sun 2003; Ardley and Robinson 2004; Herrmann et al. 
2004). Understanding the roles played by ubiquitination in the etiology 
and progression of the human disorders sure will significantly advance 
our knowledge of these diseases and shed light on developing new 
treatments to prevent and cure these illnesses. The fact that E3s 
(together with E2) define substrate specificity and the presence of 
hundreds of E3s in the human genome means that they are good 
disease targets. This is also true for DUBs, which cooperate with E3s in 
fine-tuning the states of ubiquitin pathway substrates. Most of the 
diseases with a contribution from the ubiquitin pathway can be roughly 
divided into two categories: diseases caused by dysfunctional substrates 
of the ubiquitin pathway, and diseases caused by mutations in ubiquitin 
pathway components― especially the evolutionally diverse ubiquitin 
ligases and deubiquitinating enzymes. 
 
Diseases caused by mutations of ubiquitin pathway substrates 
Nedd4 and Liddle’s syndrome 
Liddle’s syndrome is an autosomal dominant inherited form of 
hypertension caused by mutations in the carboxyl-terminus of β or γ 
subunits of ENaC. Subunits of ENaC at the cell surface are 
multiubiquitinated by Nedd4-2, through the interaction of the PY motifs 
located at the carboxyl-terminal of the ENaC subunits and the WW2 
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domains of Nedd4-2. These ubiquitinated ENaC channels may be 
internalized to downregulate their activity. The Liddle’s syndrome- 
associated ENaC mutations delete or disrupt these PY motifs, and thus 
prevent Nedd4-2-mediated ubiquitination and downregulation of ENaC 
cell membrane distribution. Elevated epithelial distribution of ENaC leads 
to excessive re-absorption of sodium and water in the renal tubules, 
resulting in chronic hypertension (Staub et al. 1997; Snyder et al. 2004; 
Wiemuth et al. 2007). 
 
Ubiquitin and neurodegenerative diseases 
A hallmark of most neurodegenerative diseases, such as 
Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and 
Kennedy disease, is the presence of insoluble intracellular protein 
aggregates. Involvement of the ubiquitin pathway in such chronic 
conditions was suggested by the presence of ubiquitin conjugates as 
well as ubiquitinated cellular proteins in the prominent aggregates. 
However, the precise role of the ubiquitin system in the pathogenesis of 
these diseases is still under assessment. The emerging theory is that the 
ubiquitin-containing aggregates reflect a failure of the ubiquitin pathway 
to clear toxic cellular proteins because of overstressed proteasomal 




Diseases related to malfunctions of ubiquitin pathway components 
Mdm2, E6AP, p53 and cancers 
A pivotal coordinator of the cell stress response, cell-cycle control 
and apoptosis, the p53 tumor suppressor is under tight regulation to 
maintain a low steady-state cellular level. Under extrinsic stresses such 
as DNA damage, the p53 level is increased, which leads to the halt of 
cell-cycle progression and the activation of DNA repair machinery, or 
apoptosis cascades if the stress is overwhelming. p53 thus protects the 
cells from undergoing oncogenic transformation. Ubiquitination of p53 
plays an important role in the stringent control of p53 level, with the 
RING finger domain protein Mdm2 as the major E3 that mediates p53 
ubiquitination and degradation. Elevated level of Mdm2, especially 
resulting from gene amplification, is detected in various human cancers. 
It may cause cancer through over-ubiquitination and degradation of p53, 
which leads the cells tolerant to DNA damage and undergo tumorigenic 
transformation (Momand et al. 1998; Onel and Cordon-Cardo 2004; 
Brooks and Gu 2006; Ciechanover 2006). 
 
Mdm2 is not the only E3 involved in p53 degradation in cancers. 
As described above, while normally not an E3 for p53, the HECT domain 
E6AP is geared into mediating p53 degradation through binding viral E6 
proteins. As the presence of E6 decrease the levels of p53, the already 
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low p53 levels predisposes the development of cervical cancer in HPV 
affected patients. 
 
SCFSkp2, p27 and cancers 
Like p53, p27 is another tumor suppressor regulated by the 
ubiquitin pathway. Downregulation of p27 is related to oral carcinoma, 
breast cancer, prostate cancer, lung cancer and lymphomas. p27 plays 
an important role in both cell proliferation and tissue differentiation, 
through binding and inhibition of cyclinE/CDK2 and cyclinA/CDK2 
complex activity. Because these cyclin/CDK2 complexes are essential 
for initiating the G1 to S phase transition, p27 acts as a negative cell-
cycle regulator and arrests cell-cycle progression.  SCFSkp2 is the 
ubiquitin ligase that mediates p27 ubiquitination, where the S-phase 
kinase-associated protein 2 (Skp2) is the F-box protein that recognize 
p27. An inverse relationship between p27 and Skp2 levels has been 
demonstrated in several kinds of human cancers. Amplification of the 
chromosome region containing skp2 is observed in tumors. The 
oncogenic potentials of Skp2 was also shown by its ability to transform 
nude mice and cultured cells (Gstaiger et al. 2001; Hershko et al. 2001; 
Yokoi et al. 2002; Yokoi et al. 2004).  
 
BRCA1, BARD1 and breast and ovary cancers 
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Inheritance of a mutant copy of the breast cancer specific tumor 
suppressor protein 1 (BRCA1) is related to remarkably high susceptibility 
to breast cancer and ovarian cancer.  BRCA1 is a RING finger domain 
E3 that is involved in DNA damage repair, cell-cycle regulation and 
transcription activation. The relevance of BRCA1 E3 function to breast 
cancer is supported by the finding that all mutations related to cancer 
susceptibility are located in the RING domain. BRCA1 pairs with BARD1 
(BRCA1 Associated RING Domain protein1) to form a more stable and 
efficient E3 heterodimer than BCA1 alone. BARD1 is a RING finger 
domain protein as well, although no E3 activity has been detected from it 
alone. BARD1 is also implicated in breast cancer. Although their 
relevance to cancer predisposition is elusive, many proteins are 
ubiquitinated by the BRCA1-BARD1 heterodimer in vitro, including 
several histones, RNA polymerase II and p53. Recently, ERα (estrogen 
receptor α), which is mono-ubiquitinated by BRAC1-BARD1, has been 
suggested as a substrate for the BRCA1/BARD1 ubiquitin ligase relevant 
to breast cancer. This might reconcile the discrepancy between 
ubiquitous BRCA1 expression and the tissue-specific cancer 
susceptibility of the breast and the ovary (Boulton 2006; Eakin et al. 
2007; Huo et al. 2007).  
 
pVHL and von Hippel-Lindau disease 
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von Hippel-Lindau disease is an autosomal dominant familial 
cancer syndrome that predisposes individuals to hypervascular tumors in 
a variety of organs. This disease is cause by mutations of one copy of 
the VHL gene, encoding the VHL tumor suppressor protein. VHL is a 
subunit of a RING domain E3 complex (ECV or VHL) composed of 
Cullin2, RBx1/Hrt1, Elongin B (a ubiquitin-like molecule) and Elongin C 
(a Skp1-related molecule). Among multiple substrates of VHL identified, 
the transcription factor HIFα (hypoxia-inducible factor 1-α) is the most 
established target of VHL. Under normoxic or hyperoxic conditions, VHL 
mediates the ubiquitination and proteasomal degradation of HIFα, 
whereas under hypoxic conditions, this regulation is inhibited.  Through 
forming a heterodimer with the constitutive HIFβ, HIFα transactivates a 
broad array of hypoxia-inducible genes, including vascular endothelial 
growth factor (VEGF), erythropoietin (EPO) and glucose transporter-1 
(GLUT1). HIFα-promoted expression of such hypoxia-inducible genes 
can explain, at least partially, the characteristic hypervascular 
tumorigenesis in VHL disease, where lack of functional VHL results in 
high subcellular levels of HIFα due to failure of HIFα ubiquitination and 
degradation (Haase 2006; Ke and Costa 2006; Ohh 2006).  
 
CYLD and cylindromatosis 
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Mutations in deubiquitinating enzyme encoding genes are also 
related to tumorigenesis. Originally identified as the tumor suppressor 
gene involved in familial cylindromatosis, cyld encodes the 
deubiquitinating enzyme CYLD. Cylindromatosis is an autosomal 
dominant predisposition to development of multiple benign tumors of the 
skin appendages. Substrates of CYLD include IKKγ (IκB kinase γ), 
TRAF2 (Tumor Necrosis Factor Receptor-Associated Factor 2) and 
TRAF6. CYLD thus negatively regulates the crucial NF-κB pathway 
associated with inflammation, immunity response and apoptosis. CYLD 
specifically disbands Lys63-linked polyubiquitin chain, not Lys48-linked 
ones (Brummelkamp et al. 2003; Kovalenko et al. 2003; Trompouki et al. 
2003). Recently, studies done with cyld-deficient mice demonstrated that 
CYLD also removes Lys63-polyubiquitin chain from Bcl-3, and thus 
hinders its nuclear translocation. As ubiquitination and nuclear 
accumulation of Bcl-3 is the prerequisite step for activating transcription 
of a subclass of NF-κB target genes, including cyclin D1, CYLD hence 
modulate the function of the NF-κB pathway in controlling cell 
proliferation and oncogenesis. (Ikeda and Dikic 2006; Massoumi et al. 
2006) 
 
Parkin, UCH-L1 and Parkinson’s disease 
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Autosomal recessive juvenile parkinsonism (AR-JP) is the rare 
familial form of Parkinson’s disease and is linked to mutations in the 
parkin gene which encodes a RING finger domain ubiquitin ligase. AR-
JP associated parkin mutations abolish the protein’s E3 function. It was 
speculated that subcellular accumulation of one or more substrates of 
Parkin due to failure in proteasomal degradation is detrimental to 
dopaminergic neurons and causes Parkinson’s disease (Hattori and 
Mizuno 2004; Wood-Kaczmar et al. 2006). More than ten cellular 
proteins have been identified as Parkin targets, including α-synuclein, 
synphilin-1 and parkin-associated endothelin-receptor-like receptor 
(PAEL). Whether subcellular accumulation of these substrates leads to 
Parkinson’s disease and if so, how, is unclear (Wood-Kaczmar et al. 
2006).  
 
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is another 
ubiquitin pathway component implicated in Parkinson’s disease. UCH-L1 
is a deubiquitinating enzyme and mutations in UCH-L1 cause autosomal 
dominant Parkinson’s disease (Wood-Kaczmar et al. 2006). In addition, 
a polymorphic UCH-L1Ser18Tyr variant displays protective effect again 
sporadic Parkinson’s disease in some ethnic groups, although not others 
(Mellick and Silburn 2000; Zhang et al. 2000; Levecque et al. 2001; 
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Satoh and Kuroda 2001; Wang et al. 2002; Elbaz et al. 2003; Miller and 
Wilson 2003; Wood-Kaczmar et al. 2006; Carmine Belin et al. 2007). 
 
Interestingly, it was found recently, that both parkin and UCH-L1 
have dual functionalities.  In addition to assembling Lys48-linked 
polyubiquitin chain onto substrate(s), parkin also promotes formation of 
Lys63-linked polyubiquitin chains (Doss-Pepe et al. 2005). As for UCH-L1, 
in addition to its DUB function, it also possesses ubiquitin ligase activity 
(Liu et al. 2002). Furthermore, a substrate for parkin and UCH-L1 
mediated Lys63-linked polyubiquitin chain attachment, α-synuclein, also 
stimulates assembly of lysine63-linked ubiquitin conjugates  through an 
unknown mechanism (Doss-Pepe et al. 2005; Liu et al. 2007). These 
findings suggest that in addition to compromised ubiquitin-proteasomal 
degradation, ubiquitination might be interwoven in Parkinson’s disease 





UBE3A/E6AP AND ANGELMAN SYNDROME 
 
Epidemiology and Clinical Features of Angelman Syndrome 
Angelman syndrome (AS) is a neurodevelopmental disorder that 
affects both sexes. Studies on AS have been reported from various 
countries, including, but not limited to, United States, Canada, France, 
Italy, Finland, Demark, Sweden, Switzerland, Russia, Australia, Brazil 
and Japan (Petersen et al. 1995; Mglinets et al. 1996; Steffenburg et al. 
1996; Fung et al. 1998; Malzac et al. 1998; Baumer et al. 1999; Russo et 
al. 2000; Rapakko et al. 2004; Varela et al. 2004; Saitoh et al. 2005; 
Dion et al. 2007). The prevalence of AS is estimated to be between 1 in 
10,000 and 1 in 20,000 births (Williams 2005). Clinical features of AS 
include severe developmental delay, mental retardation, speech 
impairment, ataxic gaits and jerky movements. The abandoned original 
name, “happy puppet” syndrome, reflects the characteristic happy and 
social nature of AS patients and the easiness in provoking excessive 
and sometimes inappropriate laughing from the affected children. 
Seizures, sleep disorders, microcephaly, abnormal EEG patterns and 
subtle dysmorphic facial features, such as wide-opening mouth, large 
chin and deep-set eyes, are also seen in some patients (Clayton-Smith 




Genetic Mechanisms of Angelman Syndrome 
Angelman syndrome is caused by genetic defects in the 
chromosome 15q11-q13 region, which is subject to genomic imprinting 
of the paternal chromosome (Clayton-Smith and Laan 2003; Sahoo et al. 
2005). To date, AS cases are divided into five classes according to the 
genetic mechanisms leading to this disorder: (I) Large interstitial deletion 
of the maternal chromosome 15q11-q13 region. This kind of defect is the 
most prevalent and found in ~70% of AS cases. The majority of the 
deletions are 3~4Mb in size. (II) Paternal uniparental disomy (UPD), 
where both copies of chromosome 15 are paternal-derived. This occurs 
in ~5% of AS patients. Given that the 15q11-13 region is subject to 
paternal silencing, in these individuals, gene(s) related to AS are not 
expressed from either chromosome. (III) Imprinting defects (ID), which 
account for ~5% of all AS cases. In those cases, maternal copies of the 
gene(s) relevant to AS in the 15q11-13 region are silenced through 
abnormal imprinting. (IV) UBE3A mutations. The UBE3A gene is located 
in the 15q11-13 region. In ~10% of AS cases, mutations in this gene 
have been found. These mutations could be point mutations, small 
(<15bp) deletions or insertions. (V) Unknown. For 10% of the AS 
patients, no chromosome 15 abnormality has been detected (Russo et al. 




Correlations between the genetic mechanisms and clinical 
severity are also observed. In comparison to other classes, patients from 
Class I and Class V display more severe symptoms, such as frequent 
seizures and absence of speech. Class II and Class III patients are the 
least severe cases. Class IV lies in the middle of Class I/V and Class 
II/III (Lossie et al. 2001; Clayton-Smith and Laan 2003; Lalande and 
Calciano 2007). The underlying molecular mechanism for such 
phenotypic discrepancies present in different AS classes is not clear. For 
Class I, it was speculated that haplo-insufficiency of other genes 
encompassed in the 15q11-13 deletion contributes to the severe clinical 
manifestations (Lossie et al. 2001; Clayton-Smith and Laan 2003).  
 
UBE3A, residing in the 15q11-13 region was identified as the 
pathogenic gene of AS in 1997, as intragenic UBE3A mutations were 
isolated from AS patients lacking of maternal deletion, paternal UPD or 
imprinting defects in the vital 15q11-13 region (Kishino et al. 1997; 
Matsuura et al. 1997). The fact that class IV patients display typical AS 
phenotypes argues that absence or disruption of expression of UBE3A 
from the maternally inherited chromosome (the only one that expresses 
UBE3A) is the cause of the major clinical deficits in AS cases through 
known genetic mechanisms (class I~IV). For the Class V (unknown) 
group, there may be mutations in the non-coding region of UBE3A. 
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Another possibility is that the patients in this class carry mutations in 
other genes controlling UBE3A expression or function, such as genes in 
the ubiquitin pathway that might interact and modify UBE3A function.  It 
is equally likely that mutations in genes encoding UBE3A substrates or 
other downstream components are responsible for AS development in 
the group (Lossie et al. 2001; Clayton-Smith and Laan 2003).  
 
Current Hypothesis for Pathogenesis of Angelman Syndrome  
The UBE3A gene encodes the UBE3A (also known as E6AP, see 
above) ubiquitin protein ligase. The genomic DNA sequence for UBE3A 
covers more than 120kb, composed of sixteen exons (Kishino and 
Wagstaff 1998). There are three isoforms of UBE3A/E6AP resulting from 
alternative splicing, which are different at their amino-termini (Yamamoto 
et al. 1997). It is not clear which isoform is the predominant one in the 
brain, nor if they are differentially relevant to AS. All AS-associated 
UBE3A mutations affect all three isoforms. The majority of all UBE3A 
mutations known to date (Table 1.1) are frameshifts and nonsense 
mutations, resulting in premature stop codons and carboxyl-terminally 
truncated proteins (Kishino et al. 1997; Matsuura et al. 1997; Fung et al. 
1998; Malzac et al. 1998; Tsai et al. 1998; Baumer et al. 1999; Fang et 
al. 1999; Huang et al. 1999; Moncla et al. 1999; Russo et al. 2000; 
Lossie et al. 2001; Burger et al. 2002; Rapakko et al. 2004). As the 
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HECT domain is carboxyl-terminal, this suggests that these mutations 
are loss-of-function mutations and that the impairment of UBE3A/E6AP 
ubiquitin ligase function is critical to the disease state (Lalande and 
Calciano 2007). In addition, missense mutations or other mutations that 
alter amino acids have been identified (Table 1.1). For three of such 
mutations, S349P, R506C and M802MI (in-frame insertion of an 
isoleucine), the clinical manifestations are not distinguishable from 
patients carrying frameshift or nonsense mutations (Malzac et al. 1998; 
Baumer et al. 1999). For the C21Y missense mutation, however, milder 
clinical phenotypes were reported (Matsuura et al. 1997; Fang et al. 
1999). No clinical phenotypic descriptions for the remainder of the AS-
associated amino acid changes are available.  
 
A simple model for how UBE3A/E6AP deficiency leads to AS 
phenotypes is that loss-of-function UBE3A/E6AP mutants fail to 
ubiquitinate and subsequently degrade its normal substrate(s). The 
subcellular accumulation of the substrate protein(s) is detrimental for 
neuronal development and/or function and leads to AS. Another 
possibility is that UBE3A/E6AP mono-ubiquitinates its substrate(s), thus 
modulating their functions. As biochemical experiments indicate that the 
polyubiquitin chains produced by UBE3A/E6AP are Lys48-linked (Wang 




Site Mutation Reference 
Exon 8  645insA  Malzac et al. 1998 
Exon 8 762–763insGA  Baumer et al. 1999 
Exon 8 856delG Fang et al. 1999 
Exon 9  897insA  Russo et al. 2000 
Exon 9  904del5 Fang et al. 1999 
Exon 9 946delAG van den Ouweland et al.1999 
Exon 9  980delAG Lossie et al. 2001  
Fang et al. 1999 
Exon 9 1296insT  Baumer et al. 1999 
Exon 9 1461del14  Malzac et al. 1998 
Exon 9 1522delG  Malzac et al. 1998 
Exon 9 1552delA Lossie et al. 2001  
Fang et al. 1999 
Exon 9 1559del7 Fang et al. 1999 
Exon 9 1694del4 Fang et al. 1999 
Exon 9 1930del 2 Lossie et al. 2001 
Exon 9 1930delAG Matsuura et al. 1997  
Fung et al.1998  
Fang et al. 1999  
Rapakko et al. 2004 
Exon 9  2037del10  Malzac et al. 1998 
Exon 10  2230del26insA  Malzac et al. 1998 
Exon 11  2376delG  Baumer et al. 1999 
Exon 12  2527insA  Malzac et al. 1998 
Exon 12  2544insA  Russo et al. 2000 
Exon 12 2567ins4 Fang et al. 1999 
Exon 16 3027insT van den Ouweland et al.1999 
Exon 16  3033insA  Malzac et al. 1998 
Exon 16 3076ins4 van den Ouweland et al.1999 
Exon 16  3086ins5  Kishino et al. 1997  
Malzac et al. 1998  
Exon 16  3092delA Lossie et al. 2001 
Exon 16  3093del 4 Fang et al. 1999  
Lossie et al. 2001  
Rapakko et al. 2004 
Exon 16  3120ins16  Baumer et al. 1999 
Intron 9  IVS9-8A G Kishino et al., 1997  
Malzac et al. 1998  
Nonsense Mutations
Site Mutation  Reference 
Exon 9  1085G T E167X Russo et al. 2000 
Exon 9 1500G A W305X Fang et al. 1999 
Exon 9   1835C T R417X Lossie et al. 2001  




   Matsuura et al.,1997 
Exon 9   2030C T R482X Malzac et al. 1998  
Lossie et al. 2001  
Russo et al. 2000 
Exon 9  2033 A T R483X Lossie 2001 
Exon 9  2185T G Y533X Fang et al. 1999 
Exon 15  2890G A W768X Tsai et al.,1998  
Fang et al. 1999 
Missense Mutations/In-frame Insertions or Deletions
Site Mutation Reference 
Exon 8 648G A C21Y Lossie et al. 2001  
Fang et al. 1999  
Matsuura et al.,1997 
Exon 9  902A C T106P  Rapakko et al. 2004 
Exon 9  975T C I130T  Rapakko et al. 2004 
Exon 9   1631T C S349P  Malzac et al. 1998 
  L502P Huang et al. 1999 
Exon 9  2102C T R506C Baumer et al. 1999 
  E550L Huang et al. 1999 
Exon 15 2929del3 F782∆ Fang et al. 1999 
Exon 15 2992ins3 M802MI Malzac et al. 1998 
Exon 15 2997T A I804K Fang et al. 1999 
Exon 16  3142del15     Elongated protein Fang et al. 1999 
Other AS-associated Mutations
Site Mutation Reference 
Intron11 -12del7 van den Ouweland et al.1999 
Benign Polymorphisms
Site Mutation Reference 
Exon 8   702G A R39H Malzac et al. 1998 
Exon 9 1118G A A178T Matsuura et al.,1997  
Malzac et al. 1998  
Baumer et al. 1999  
Fang et al. 1999 
Rapakko et al. 2004 
Exon 9 1144A G         silent  mutation Lossie et al. 2001 
Exon 16  3’UTRdel14 Fung et al. 1998;  
Baumer et al. 1999 
Intron6 -47insT Lossie et al. 2001 
Intron7 GATGAT GAT Fang et al. 1999 
Intron12 T C Baumer et al. 1999 
 
Table 1.1: Benign polymorphism and Angelman syndrome-related 
mutations in UBE3A . Nucleotide and amino acid positions are according 




Although several proteins have been identified as the constitutive 
substrates of E6AP or UBE3A, including HHR23A, Blk and Mcm7 (see 
above). The relevance of these substrate(s) to the pathophysiology of 
AS is unclear.  
 
Mouse Models for Angelman Syndrome 
Several AS mouse models have been established and provide 
valuable research tools for study of this disorder. Mouse chromosome 
region 7C containing the mouse UBE3A gene corresponds to human 
chromosome 15q11-13 and is also subject to imprinting. The first AS 
model utilizes mice with partial paternal disomy of chromosome 7 (UPD). 
These mice display AS analogous phenotypes, such as growth 
retardation, deficient locomotor skills, hyperactivity, reduction in brain 
weight and a salient AS-characteristic EEG abnormality (Cattanach et al. 
1997). RNA in situ hybridization analyses using these paternal UPD 
mice demonstrate preferential expression of the maternal murine UBE3A 
copy in Purkinje cells, hippocampal neurons and mitral cells of the 
olfactory bulbs (Albrecht et al. 1997). This is among the first reports of 
brain-specific imprinting of mammalian UBE3A, which also highlights the 
association of AS-like phenotypes with certain brains regions. Mice 
carrying a large chromosome 7C deletion (Gabriel et al. 1999) or 
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imprinting defect (Gabriel et al. 1999; Wu et al. 2006) are also reported 
as models of AS. In addition, two UBE3A-specific knock-out mouse 
models have been generated through targeted inactivation of UBE3A 
(Jiang et al. 1998; Miura et al. 2002). Impaired behaviors of these mice 
mimic AS phenotypes: locomotor dysfunctions, defective hippocampus-
dependent learning and abnormal EEG are observed with both maternal 
chromosome UBE3A-deficiencent models. Predominant expression of 
UBE3A from the maternally inherited chromosome in the hippocampus 
and the cerebellar Purkinje cell layer is also confirmed in these UBE3A 
knock-out mice. Sleep disorders are also detected in the UBE3A 
maternal chromosome-deficient mice model developed by Miura et al. 
(2002). Jiang et al. (1998) also described the presence of inducible 
seizures and impaired hippocampal long-term potentiation (LTP) in their 
mouse model, which first suggested a potential correlation between the 
cognitive deficits in AS and aberrant LTP. Further investigations of these 
mice led to the proposal that disruption of calcium/calmodulin-dependent 
kinase type 2 (CaMKII) activity regulations is related to the LTP deficit in 
AS mice, and very likely the mental retardation symptoms in AS humans. 
Significantly decreased enzymatic activities of protein phosphatases 1 
(PP1) or PP2A, the major phosphatases for CaMKII may be responsible 
for the misregulation of CaMKII. In the AS mouse brain, elevated 
phospho-CaMKII at sites Thr285 and Thr305 and reduced CaMKII 
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activity is detected in the hippocampus, even though the total level of 
CaMKII is unaltered (Weeber et al. 2003). Remarkably, many AS-like 
phenotypes caused by murine maternal chromosome UBE3A-deficiency 
are rescued by the presence of CaMKII Thr305Val/Thr306A, whose 
mutations prevent the inhibitory phosphorylation of CaMKII (van 
Woerden et al. 2007). This suggests that CaMKII malfunction contributes 
to the overall neurological defects in AS. Neither CaMKII nor its 
phosphatases PP1/PP2A are likely the direct target of UBE3A/E6AP-
mediated ubiquitination/degradation, as no changes in total 
concentrations of CaMKII or these phosphatases are detected in brains 
of the mouse model (Weeber et al. 2003). The crucial cellular protein(s) 





Drosophila DISEASE MODELS 
 
Reasons for Utilizing the Fruit Fly to Model Human Diseases  
For more than a hundred years, Drosophila melanogaster (the 
fruit fly) has been an appealing model organism to study all kinds of 
biological phenomena. The well-developed genetic tools available and 
the completion of the fly genome project make the fruit fly an attractive 
system for doing both forward and reverse genetics. An emerging theme 
is to use the fruit fly to model human diseases, given that many 
pathogenic genes of human disorders have conservative homologs in 
the fly. By comparing the human genome and the D. melanogaster 
genome, it was reported that over 75% of the known human disease 
genes can find their orthologs in the fly genome (Rubin et al. 2000; 
Reiter et al. 2001).  
 
Investigation of the genetic and molecular functions of the fly 
counterparts of such pathogenic genes can be achieved by making 
gene-specific knock-out mutants or by ectopically expressing the fly or/ 
and the human genes using the bipartite Gal4-UAS system (Brand and 
Perrimon 1993). The latter is especially amenable to genetic 
manipulation with the vast collection of Gal4 drivers enabling the highly 
specialized temporal and spatial expression of the transgenes in virtually 
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any fly tissue. Many genes, even those without apparent morphological 
knock-out phenotypes, when misexpressed with the Gal4-UAS system, 
give rise to morphological defects. These easy-to-screen-for phenotypes 
can be used as backgrounds for genome-wide genetic modifier screens. 
In addition to the traditional mutagens, such as EMS and X-ray radiation, 
to generate de novo mutations throughout the entire genome, the 
availability of growing collections of isogenized deficiency chromosomes 
and P element insertion lines will speed up the screen processes and 
the discovery of genes in the disease pathways. The identification of 
genes in the pathways of the human disease homologs will lead to the 
understanding of the functions of the disease genes and shed light on 
the underlying mechanism of disease pathogenesis. For many disease 
genes that are essential for fly viability, the powerful FLP-FRT technique 
enables the study of classical homozygous knock-out mutants in special 
tissues in the otherwise heterozygous flies (Golic 1991).  
 
Drosophila models for neurodevelopmental diseases, 
neurodegenerative diseases and cancers have been well established 
(Bilen and Bonini 2005; Cauchi and van den Heuvel 2006). The 
realization that the functions of the heart, the kidney and the immune 
system are conserved from fly to human also makes the fruit fly a 
promising model system for cardiovascular diseases, kidney diseases 
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and infectious diseases (Bier and Bodmer 2004; Brumby and 
Richardson 2005; Marsh and Thompson 2006; Sanchez-Martinez et al. 
2006; Vidal and Cagan 2006; Ocorr et al. 2007). These models not only 
provide a platform for in vivo analyses of the developmental and cellular 
behaviors of diseases genes and proteins, they also provide rapid and 
economic testing systems for therapeutic drugs.  
 
Fly Models for Neurodegenerative Diseases 
“Neurodegenerative diseases” is the collective description for over 
thirty clinical disorders caused by progressive loss of neurons. 
Characteristic symptoms for this class of diseases are ataxia and 
declining cognitive function (dementia). The representative 
neuropathological feature for these conditions is the formation of 
intracellular filamentous aggregates. The major protein components of 
the intracellular inclusions differ among neurodegenerative diseases. 
Prevalence of these devastating chronic neurological disorders rises 
over time, given the lengthened life expectancy of man and the fact that 
most of them are late-onset. No effective treatments are currently 
available (Ardley and Robinson 2004; Marsh and Thompson 2004; 
Troulinaki and Tavernarakis 2005). A growing list of neurodegenerative 
diseases modeled in fly includes Huntington’s disease (HD), Alzheimer’s 
Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis 
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(ALS), Spinocerebellar Ataxia (SCA), Kennedy disease (KD) and 
hereditary spastic paraplegia (HSP) (Merry 2005; Cauchi and van den 
Heuvel 2006).  
 
Fly models for Polyglutamine diseases 
Polyglutamine (PolyQ) diseases, with HD as the classical 
representative, refer to a group of disorders caused by CAG codon 
expansion, resulting in the incorporation of abnormally long glutamine 
stretches in the affected proteins. Such aberrant proteins are the major 
components of nuclear inclusions, a typical pathological feature shared 
by the PolyQ diseases. Most diseases in this collection show autosomal 
dominant inheritance, except Kennedy disease, which is X-linked (Merry 
2005; Mutsuddi and Rebay 2005; Cauchi and van den Heuvel 2006).  
 
Fly models for HD and other PolyQ diseases were generated by 
misexpression of full-length or truncated human PolyQ-expanded 
proteins, such as Huntingtin (Htt) protein for HD (Jackson et al. 1998; 
Lee et al. 2004), androgen receptor (hAR) for KD (Chan et al. 2002; 
Takeyama et al. 2002), and ataxin-1, ataxin-3 and ataxin-7 for SCA-1 
(Fernandez-Funez et al. 2000), SCA-3/Machado-Joseph disease 
(Warrick et al. 1998) and SCA-7 (Latouche et al. 2007) respectively. In 
fact, direct expression of excessive epitope tagged polyQ peptide is 
 38
 
sufficient to introduce neuropathology (Kazemi-Esfarjani and Benzer 
2000; Marsh et al. 2000). Mutant phenotypes exhibited by these fly 
models mirror well the central characteristics of PolyQ diseases in many 
aspects. For example, the presence of distinguishing nuclear inclusions 
in affected cells and late on-set progressive cell degeneration are highly 
proportional to the number of the CAG repeats. Decreased life span and 
locomotor activity were demonstrated in fly models, when mutant 
proteins were targeted for nervous system expression (Warrick et al. 
1998; Marsh et al. 2000; Lee et al. 2004; Latouche et al. 2007).  
 
These fly models have made enormous contributions to 
identifying molecular mechanisms underlying the pathophysiology. 
Unbiased genetic screens for dominant modifiers of neurodegenerative 
eye phenotypes of the fly models (Fernandez-Funez et al. 2000; 
Kazemi-Esfarjani and Benzer 2000; Bilen et al. 2006) have revealed 
various cellular pathways and processes involved in the polyQ-mediated 
neuronal degeneration. Protein folding chaperone proteins have been 
isolated as genetic modifiers of the eye defects in both the SCA-1 model 
(Fernandez-Funez et al. 2000) and the tag-polyQ peptide model 
(Kazemi-Esfarjani and Benzer 2000). The ubiquitin pathway is implicated 
in the neuronal pathogenesis, as ubiquitin and other Ub pathway 
components were isolated in the SCA-1 screen (Fernandez-Funez et al. 
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2000). Transcriptional factors compose another group of modulators of 
the SCA-1 eye phenotype (Fernandez-Funez et al. 2000). This offers 
persuasive support for the relevance of transcriptional regulation to 
polyQ disease, as the toxicity of the nuclear inclusions was speculated to 
repress transcription. An interesting class of genetic modifiers is made 
up of genes involved in RNA regulation. While several RNA binding 
proteins were recovered in the SCA-1 screen (Fernandez-Funez et al. 
2000), the involvement of microRNA pathway in neurodegeneration were 
first described in a similar screen for genes that alter the SCA-3 eye 
phenotype (Bilen et al. 2006).  
 
These fly models also provide an in vivo system for evaluating 
candidate genes speculated to play roles in polyQ disease pathogenesis 
as well. The possible relevance of histone acteylation/ deacetylation 
balance-monitored transcription control (Steffan et al. 2001; Taylor et al. 
2003), post-translational protein modification and protein folding (Warrick 
et al. 1999; Chan et al. 2002; Steffan et al. 2004) as well as the 
microRNA pathway (Bilen et al. 2006) to polyQ-mediated degeneration 
were examined in fly polyQ models.  
 
Drosophila polyQ models are also valued for their efficiency in 
low-cost in vivo screens for promising therapeutic molecules identified 
 40
 
through high-throughout biochemical screens (Kaltenbach et al. 2007). 
Even though it might seem intimidating to utilize invertebrates for 
selecting future drugs, the therapeutic effects of the histone deacetylase 
(HDAC) inhibitors in the fly (Steffan et al. 2001) were comparable to 
those in the mouse (Ferrante et al. 2003; Hockly et al. 2003). This 
argues strongly for the potentials of the fly model for preliminary in vivo 
chemical assessment.  
 
Fly models for Alzheimer’s disease  
AD is the leading cause of senile dementia, with two cardinal 
histopathological markers— the extracellular  amyloid plaques 
composed of the β-amyloid peptides (Aβs) and tau protein-based 
intracellular neurofibrillary tangles. Aβs are the proteolytic fragments of 
the amyloid precursor protein (APP), which is cleaved by β-secretase 
and Presenilin-based γ-secretase. There are two forms of Aβs, Aβ40 and 
Aβ42. It was proposed that excessive production of the sticky Aβ42, due 
to increased APP expression or aberrant APP cleavage, initiates AD 
pathogenesis (Bilen and Bonini 2005; Cauchi and van den Heuvel 2006).  
 
Given that fly APP lacks sequence homology at the Aβ region 
(Rosen et al. 1989), fly AD models have been established through 
misexpression of Aβ42 or human APP, which leads to neurodegenerative 
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defects, such as compromised locomotor ability and shortened life span. 
These models provide in vivo evidence for the proposed mechanism of 
APP processing and Aβ toxicity (Finelli et al. 2004; Greeve et al. 2004; 
Iijima et al. 2004; Crowther et al. 2005). They are also useful for 
screening/assaying genetic modifiers of Aβ neurotoxicity (Finelli et al. 
2004; Kinghorn et al. 2006) or pharmacological ones (Greeve et al. 2004; 
Crowther et al. 2005).  
 
Furthermore, research in Drosophila provides insights into the 
physiological functions of fly and human APP homologs in neurons 
(Torroja et al. 1999; Torroja et al. 1999; Gunawardena and Goldstein 
2001; Merdes et al. 2004; Leyssen et al. 2005; Rusu et al. 2007). These 
findings may well be extended into mouse or human systems, as 
exemplified by the involvement of APPs in axonal transport in both flies 
and vertebrates (Torroja et al. 1999; Gunawardena and Goldstein 2001; 
Stokin et al. 2005). The fruit fly also provides an practical system for 
analyzing the normal function of Presenilin (Lu et al. 2007) as well as in 
vivo molecular properties of AD-related presenilin mutants (Ye and 
Fortini 1999; Seidner et al. 2006).  
 
Neurofibrillary tangles composed of hyperphosphorylated tau, a 
microtubule-binding protein, are another characteristic pathological 
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feature of AD. Parallel to Aβ fly models, misexpression of normal or 
mutant human tau in flies were used for probing the mechanism of tau-
associated neurodegeneration (Wittmann et al. 2001; Jackson et al. 
2002; Chee et al. 2005). Although, the tau proteins in these models are 
hyperphosphorylated, no neurofibrillary tangles were observed. These 
thus provide in vivo evidence for the uncoupling of these two cellular 
events. A genetic screen for modifiers of tau toxicity (Ghosh and Feany 
2004) recovered a large class of protein kinases and phosphatases, 
suggesting that phosphorylation of tau is important. These screen results 
are dramatically different from the types of modifiers yield from the polyQ 
model screen (as above).  This significant difference suggests that 
divergent molecular mechanisms underline neurodegenerative diseases 
sharing overlapping clinical and pathological features. As with all fly 
disease models, the tau overexpression flies were used for candidate 
gene analyses as well (Jackson et al. 2002; Ghosh and Feany 2004). 
 
Fly model for Parkinson’s disease  
The discoveries of PD causative genes related to the rare forms 
of familial PD help in advancing our knowledge of pathogenesis of both 
hereditary and sporadic PD. The list of these PD genes includes α-
synuclein, parkin, DJ-1, PTEN-induced putative kinase 1 (Pink-1), and 
LRRK2/PARK8 (Wood-Kaczmar et al. 2006). Except for α-synuclein, 
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there are fly homologs for these PD causative genes (Whitworth et al. 
2006). α-synuclein mutations are associated with autosomal dominant 
PD. Misexpression of human wild-type and mutant (A30P, A53T) α-
synuclein in Drosophila leads to the first and most intensively studied fly 
PD model. α-synuclein overexpression recapitulate dopaminergic neuron 
loss, the appearance of intraneuronal proteineous aggregates 
resembling PD Lewy’s body, and locomotor deficits features of PD 
(Feany and Bender 2000). In search for a means to alter α-synuclein 
toxicity, it was found that heat-shock chaperones will do just that. α-
synuclein toxicity was alleviated genetically by HSP70 overexpression. 
Moreover, drugs that induce chaperone overexpression also alleviate α-
synuclein toxicity (Auluck and Bonini 2002; Auluck et al. 2002). The 
phosphorylation state of α-synuclein is also crucial for its neurotoxicity 
(Whitworth et al. 2006).  
 
Loss of Pink, parkin, and DJ-1 are linked to autosomal recessive 
PD. Research on their fly homologs have shed light on the physiological 
functions of these genes as well as on the underlying mechanisms for 
PD pathogenesis. Disruption of either Drosophila parkin (Greene et al. 
2003; Pesah et al. 2004; Whitworth et al. 2005) or dPink1 alone (Clark et 
al. 2006; Park et al. 2006; Yang et al. 2006) leads to muscle 
degeneration, selective loss of dopaminergic neurons, reduced life span 
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and male sterility. Mitochondrial dysfunctions underscore these loss-of-
function phenotypes. Interestingly, overexpression of parkin rescues the 
phenotypes of the pink mutant, thus putting parkin downstream of pink in 
the genetic pathway involving mitochondrial regulation. The roles of fly 
DJ-1 orthologs in oxidative stress responses are implicated consistently 
in various studies (Menzies et al. 2005; Meulener et al. 2005; Park et al. 
2005; Yang et al. 2005). Mitochondrial malfunction and oxidative stress 
have long been interwoven in the pathophysiology of neurodegenerative 
disease. The availability of fly models for PD will continue to provide vast 
opportunities to address such relevance in great detail.   
 
Fly Models for Neurodevelopmental Diseases  
Drosophila fragile X models  
Fragile X syndrome (FXS) is the leading cause of inherited mental 
retardation. This disorder is caused by mutations that disrupt the 
expression of Fragile X mental retardation gene (FMR1). FMR1 encodes 
the RNA binding protein FMRP. In human and mouse, there are two 
close paralogs of FMR1, FXR1 and FXR2, and all three constitute the 
FMR1/FXR gene family. Although the functions of FXR1P and FXR2P 
have yet to  be resolved, at least in the mice model, double FXR2 and 
FMR1 knock-out mice display stronger behavioral phenotypes than 
single knock-out mice of either gene alone, suggesting some functional 
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interactions or redundancy between these paralogs (Spencer et al. 
2006). In Drosophila, there is only one FMR1 ortholog, Drosophila fragile 
X related (dfxr) gene (Zhang et al. 2001), also called dfmr1 (Wan et al. 
2000). DFXR protein exhibits comparable degrees of identity and 
similarity to all three mammalian FMR1/FXR protein family members 
(Zhang et al. 2001). Since the first cloning of dfxr (Wan et al. 2000) and 
the characterization of dfxr knock-out flies (Zhang et al. 2001; Inoue et al. 
2002; Lee et al. 2003), the fly fragile X models have made a huge 
contribution to understanding the functions of FMRP and the possible 
mechanisms of FXS pathogenesis.  
 
Loss-of-function dfxr mutants are viable and demonstrate 
locomotor defects at both larval and adult stages, as tested in the larval 
crawling assay and adult flight test (Xu et al. 2004; Zhang et al. 2004). 
Adult dfxr mutants are also arrhythmic, underlining the role of dfxr in 
circadian output regulation (Dockendorff et al. 2002; Inoue et al. 2002; 
Morales et al. 2002). Aberrant courtship behavior is also observed in dfxr 
mutants (Dockendorff et al. 2002). The role of DFXR in regulating the 
structure of synapses or neuronal processes was suggested by the 
neurite overgrowth and overbranching phenotypes seen in different 
types of neurons (Zhang et al. 2001; Dockendorff et al. 2002; Lee et al. 
2003; Michel et al. 2004). Conversely, overexpression of dfxr using the 
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Gal4-UAS system results in defects opposite to those in dfxr knock-outs. 
The behavioral and neuronal architectural defects displayed by dfxr loss-
of-function mutants parallel with what is observed in FXS patients and 
FMR1 knock-out mice (Comery et al. 1997; Irwin et al. 2001; Irwin et al. 
2002), suggesting the evolutionary conservation of FMRP function from 
fly to human.  
 
Systemic microarray analyses have identified more than four 
hundred mRNAs associated with FMRP in the mouse brain, providing a 
daunting repertoire of potential targets of FMRP (Brown et al. 2001).   
The fly models provide an amenable in vivo system for sorting out the 
physiological mRNA target(s) responsible for fragile X. In fact, various 
mRNAs have been identified as the in vivo targets of DFXR in the fly 
nervous system, including (1) futsch mRNA, which encodes the fly 
homolog of microtubule-associated protein 1B (MAP1B), whose 
translation is repressed by DFXR (Zhang et al. 2001); (2) pickpocket1 
mRNA, encoding PPK1 from the degenerain/epithelial sodium channel 
family, which is involved in DFXR regulation of the larval crawling 
behavior (Xu et al. 2004); (3) mRNA encoding the Rho GTPase dRac1 
(Lee et al. 2003). As it was also proposed that dRac1 controls DFXR 
activity through acting on the Drosophila homolog of Cytoplasmic FMRP-
interacting protein/Sra-1 (Schenck et al. 2003), these data suggest 
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dRac1 and DFXR constitute a feedback loop; (4) mRNA encoding 
Profilin (Reeve et al. 2005). Both dRac1 and Profilin are involved in actin 
skeleton dynamics and it was suggested that dRac1 and DFXR work 
cooperatively in Profilin regulation (Reeve et al. 2005).  
 
Defects related to dfxr deficiency outside the nervous system 
were also investigated in Drosophila, and DFXR targets in such tissues 
were discovered (Zhang et al. 2004; Costa et al. 2005; Deshpande et al. 
2006; Monzo et al. 2006). trailer hitch mRNA was isolated as a target of 
dFMRP during the cleavage stage of fly embryogenesis (Monzo et al. 
2006) and orb mRNA is a target for DFXR regulation in the ovary (Costa 
et al. 2005).  
 
Drosophila FXS  models also contribute to the isolation of DFXR-
interacting proteins (Zarnescu et al. 2005; Zhang et al. 2005) and cellular 
complexes. The emergence of DFXR’s likely involvement in the RNAi 
and microRNA pathways is due to the co-isolation of  DFXR, Argonaute 
2 and other components of the RNAi machinery in cellular complexes 
(Caudy et al. 2002; Ishizuka et al. 2002). The functional relevance of 
DFXR and RNAi is confirmed, at least to some extent, by the 
observation that Argonaute 2 and DFXR collaborate in ppk1 mRNA level 
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control (Xu et al. 2004), and argonaute 1 genetically interacts with dfxr 
(Jin et al. 2004).  
 
In many cases, discoveries about FMRP were made first in the fly, 
and confirmed later in the mouse. For example, the identification of 
mammalian MAP1B mRNA as a target of murine FMRP and its 
requirement in microtubule dynamics in the neuron (Lu et al. 2004) 
extends the corresponding finding in fly (Zhang et al. 2001). Second, 
after the association of DFXR and RNAi pathway was first unveiled in 
Drosophila, the interaction between mammalian FMRP and microRNAs 
and RNAi pathways was demonstrated as well (Jin et al. 2004; Plante et 
al. 2006).  Third, the isolation of dlgl (Drosophila lethal (2) giant larvae) 
as a modifier of dfxr phenotype in a genetic screen guides the finding 
that FMR and Lgl physical associate with each other in a macromolecule 
complex in both flies and mice during neural development (Zarnescu et 
al. 2005). These examples highlight the virtues of the fly FXS models, 
which complement well the mouse models and act as forerunners for 
modeling other neurodevelopmental diseases in Drosophila. 
 
Establishing a Drosophila model for Angelman syndrome 
Although UBE3A mutations were identified as the cause of 
Angelman syndrome ten years ago, at present nothing more is 
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understood about the biochemical nature of disease. The UBE3A 
substrate(s) relevant to Angelman syndrome are still elusive.  
 
While UBE3A mutant mice provide an excellent model for 
Angelman syndrome in many regards, the mouse system has its 
inherent limitations in dissecting the biological processes that go awry in 
UBE3A deficiency. For example, it is impractical in mice to do a 
mutagenesis screen to identify the normal substrate(s) of UBE3A.  
 
The UBE3A gene is conserved among higher eukaryotes. Gene 
CG6190 annotated by the Drosophila genome project appears to be the 
fly homolog of UBE3A. The similarity between human UBE3A and 
Drosophila UBE3A (Dube3a) proteins is ~50% with the majority of the 
conserved amino acids clustering in the HECT domain. No mutant allele 
of the dube3a gene is characterized and its function in fly development is 
unknown.  
 
My goal is to develop a Drosophila AS model that will allow us to 
identify the AS-associated substrate(s) of the Drosophila UBE3A 
homolog and ultimately, to determine why the lack of UBE3A protein 
causes Angelman syndrome in humans. This knowledge could lead to 
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methods for early diagnosis and possibly treatment to control or prevent 
the disease.  
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Chapter 2: Generation and Molecular 
Characterization of dube3a Alleles 
 
INTRODUCTION 
The goal of the research is to develop a Drosophila model of 
Angelman syndrome that will be useful for identification of UBE3A 
substrates relevant to the disease in the future. To do so, I need to 
determine if disruption of the fly UBE3A homolog will causes AS-like 
defects in flies. Because human AS is caused by loss-of-function 
mutations in UBE3A, to obtain loss-of-function mutants of the fly UBE3A 
homolog and to analyze their phenotypes is a crucial first step in the 
establishment and validation of the fly AS model. 
 
RESULTS AND DISCUSSION 
A Blast search of either the human UBE3A full-length protein 
sequence or that of its HECT domain (carboxyl-terminal 350 amino acids) 
against the Drosophila genome reveals fourteen fly HECT domain 
proteins (Table 2.1). Among them, the annotated CG6190 protein is the 
most likely homolog of human UBE3A. These two proteins share 55 
percent similarity in their overall amino acid sequences and 71 percent 
similarity over their HECT domains (Figure 2.1). Unlike other fly HECT 
domain proteins, CG6190 protein has no other characteristic protein  
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# Gene Cytological 
position 
 Protein domains/ regions other 
than the HECT domain present in 
the encoded proteins 
1.  CG17735 82D5 WWE domain ARM repeat 
2.  CG3099  8F21  -- 
3.  CG3356  60C21  IQ calmodulin-binding region 
4.  CG4238  22B9 Filamin/ABP280 repeat 
5.  CG5087  66F11  IQ calmodulin-binding region 
6.  CG5604  31C4 
Ankyrin repeats 
mib/herc2 domain  
ARM repeat 
Sad1/UNC-like C-terminal 
7.  CG6190  68B12  -- 





9.  CG9153  61F6 1  RCC1 repeats 











PABP unique domain 
Zinc finger, N-recognin 
12.  Nedd4  74D2 C2 domain WW domain 
13.  Smurf 54C12 C2 domain WW domain 
14.  Su(dx)  22C1 C2 calcium/lipid-binding region WW domain 
 
Table 2.1: List of fourteen Drosophila HECT domain protein encoding 
genes in the fly genome. Among these HECT domain protein genes, 

























Figure 2.1:  Conservation of amino acid sequences of fly Dube3a and human UBE3A. Shown are the 
amino acid sequences of the three human UBE3A isoforms (Yamamoto et al. 1997), and the single 
Drosophila melanogaster Dube3a protein aligned using MacVector 9.0. Grey shading indicates 
similarity, and black shading identities. The two proteins are 39% identical and 55% similar overall, 
and the HECT domain is 56% identical and 71% similar. Missense amino acid changes in Angelman 
syndrome patients are indicated in purple, and the asterisk indicates the catalytic Cysteine residue.   
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domains outside the HECT domain (Table 2.1).  This is similar to human 
UBE3A, except that that UBE3A has a 18 amino acids long E6 binding 
site/ L2G box, which is not conserved in fly CG6190 protein (Figure 2.1).  
 
CG6190 gene is located at position 68B1 on the left arm of 
chromosome 3 and has not been characterized molecularly. The 
structure of CG6190 is derived from computational analyses of the 
genomic DNA sequence and available EST data 
(http://flybase.bio.indiana.edu/reports/FBgn0061469.html, Figure 2.2, 
Table 2.2). The CG6190 gene is also referred as dube3a (Reiter et al. 
2006), which highlights the orthological connection between Drosophila 
dube3a and human UBE3A. 
 
Due to alternative mRNA splicing, there are three different human 
UBE3A isoforms that differ at their N-termini (Yamamoto et al. 1997). 
There is no evidence for alternate isoforms of the fly protein, as ESTs 
identify only one dube3a mRNA (Figure 2.2, Table 2.2). Using RT-PCR 
and DNA sequence determination, I found this mRNA in embryos, larvae 
and adults (not shown). Virtual translation of the dube3a mRNA starting 
at the first in-frame Met residue results in a protein whose second Met 
residue, 34 codons downstream, aligns well with the initiation codon of 
human UBE3A isoform 1. I think that the first Met codon is likely to be 
 55
 
# EST Align to dube3a cDNA Expression Pattern 
1.  EN06317 2511-2938 Cultured cell-line 
2.  RE02013 24-216 Embryo 
3.  RE26015 24-604 Embryo 
4.  RE27977 24-481 Embryo 
5.  RE28250 30-608 Embryo 
6.  RE28274 30-664 Embryo 
7.  RE29433 25-671 Embryo 
8.  RE33980 21-478 Embryo 
9.  RE36891 24-474 Embryo 
10.  RE50278 24-589 Embryo 
11.  RE62574 19-723 Embryo 
12.  RE66965 16-555 Embryo 
13.  RE69002 30-610 Embryo 
14.  LD04717 44-437 Embryo 
15.  LD11513 19-706 Embryo 
16.  LD15749 68-639 Embryo 
17.  LD21888 24-3644 Embryo 
18.  LD23356.3’ 3327-3645 Embryo 
19.  LD23356.5’ 766-1491 Embryo 
20.  LD26168 68-701 Embryo 
21.  LD26277 3169-3429 Embryo 
22.  LD27716 766-1341 Embryo 
23.  LD31792 55-628 Embryo 
24.  LD33078 1-763 Embryo 
25.  LD36547 47-582 Embryo 
26.  LD38041 1-544 Embryo 
27.  LD47770 31-581 Embryo 
28.  EK132730 2070-2516 Embryo/ larval imaginal disc/ adult head 
29.  EK190022 3061-3262 Embryo/ larval imaginal disc/ adult head 
30.  LP23042 19-736 Larvae/pupae 
31.  EC39982 2705-3240 Larval third instar stage fat body 
32.  LP09860 65-580 Larvae/pupae 
33.  LP05352 1135-1758 Larvae/pupae 
34.  GM03445.3’ 3077-3654 Ovary germarium-stage 6  
35.  GM03445.5’ 1788-2480 Ovary germarium-stage 6 
36.  GM25309 44-642 Ovary germarium-stage 6 
37.  AT01473 65-735 Testes, adult 
38.  AT02553 73-493 Testes, adult 
39.  AT05579 481-1268 Testes, adult 
40.  AT10666 86-665 Testes, adult 
41.  AT16565 1539-1851 Testes, adult 
42.  AT19959 96-423 Testes, adult 
43.  AT20594 120-856 Testes, adult 
44.  AT23227 147-548 Testes, adult 
45.  AT24587 73-819 Testes, adult 
46.  AT24638 73-459 Testes, adult 
47.  AT28915 482-1164 Testes, adult 
48.  AT30647 120-786 Testes, adult 
49.  AT30695 34-736 Testes, adult 
50.  AI945680 2948-3246 Testes, adult 
51.  BE976277 805-1359 Testes, adult 
 




































Figure 2.2: Genomic organization of dube3a and ESTs for dube3a.  dube3a ESTs have been isolated 
from various fly tissues and developmental stages, including adult ovary and testis, embryos, larvae, 
pupae. In addition, one dube3a EST fragment was isolated from cultured cells. There is no evidence 
for alternative splicing of dube3a, as ESTs available so far identify only one dube3a mRNA. 
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used for two reasons. First, human isoforms 1 and 2 have N-termini that 
extend upstream of the initiator Met in isoform 1 (Figure 2.1). Second, I 
find an extended open-reading-frame in each of the eleven Drosophila 
species whose genomic DNA sequences were analyzed (Figure 2.3). 
 
A P-element allele of dube3a was generated by the BDGP 
(Berkeley Drosophila Genome Project) Gene Disruption Project. It is 
inserted in the 5’-UTR of dube3a, ~300bp upstream of the putative 
translation start site. Genomic location of this EP line was confirmed by 
PCR and DNA sequencing. The original EP allele is homozygous viable 
and no noticeable external phenotype is observed in EP homozygotes or 
in trans to several deficiency chromosomes carrying large chromosomal 
deletions, uncovering the region containing dube3a (Df (3L) vin5 [68A02-
03; 69A01-03], Df (3L) vin2 [67F02-03; 68D06] or Df (3L) vin66 [68A02-
03; 68D03]).  In comparison to w1118 controls, the presence of the EP 
insertion in the 5’-UTR of dube3a does not affect the transcription level 
of dube3a significantly, as shown in RT-PCR. Generation and analysis of 
dube3a knock-out mutants enable us to understand its endogenous 
functions.  
 
By mobilizing the EP (3)3124 element with ∆2-3 transposases, 

























Figure 2.3: The first Met codon in Dube3a computed open reading frame is likely to be the start codon 
of the endogenous Dube3a protein. We BLASTed the first 50 amino acids of the melanogaster 
sequence against eleven Drosophila species’ genome sequences, and all of them have an in-frame 
Met codon upstream of the one that aligns with human UBEA isoform 1. As in Figure 2.1, the N-





































Figure 2.4: Fly cross scheme for the generation of dube3a mutants by 
mobilizing the EP(3)3214 element inserted into the 5’-UTR of the dube3a 




are homozygous lethal or lethal in trans to deficiency chromosomes 
uncovering the dube3a region. No obvious external morphological 
defects were present in these flies. As murine UBE3A knock-out 
homozygous mice are viable with neurological defects (Jiang et al. 1998), 
I reasoned that flies lacking dube3a expression would be viable likewise. 
PCR-based identification was performed on these hop-out lines to find 
lines carrying deletions around the EP insertion site. Two imprecise 
excision mutations in dube3a were recovered and named as dube3a6J 
and dube3a8O. Through PCR and DNA sequencing, the breakpoints of 
each mutant were confirmed molecularly. dube3a6J has a ~1.7kb 
deletion within dube3a, uncovering the region from the EP insertion site 
to the middle of dube3a exon 4. dube3a8O contains a ~2.4kb deletion, 
which extends from exon 1 of CG7600, an uncharacterized gene just 
upstream of dube3a, to exon 3 of dube3a (Figure 2.6). Flies 
homozygous for either dube3a allele are viable and fertile with no 
obvious external morphological defects. This is true also for either 
dube3a6J/Df (3L) vin5 flies or dube3a8O/Df (3L) vin5 flies.  
 
RT-PCR results (not shown) from flies that are either dube3a8O 
homozygotes or dube3a8O/Df (3L) vin5 trans-heterozygotes showed that 
there is no or just trace amounts of dube3a mRNA present in these flies. 
Therefore, dube3a8O is a strong or null allele of dube3a. It might disrupt 
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function of the nearby gene, CG7600, as well (Figure 2.6). In dube3a6J 
homozygous flies, the remaining dube3a exons are still transcribed. This 
is consistent with the fact that while the dube3a transcription start point 
is gone in dube3a8O, it is still present in the dube3a6J chromosome and 
thus enables transcription initiation.  
 
Dube3a protein expression levels of both dube3a6J and dube3a8O 
in third instar larval eye discs were assayed by Western blots with 
polyclonal anti-Dube3a anti-sera (see Chapter3 for description of these 
antibodies). These anti-sera were generated in rats and guinea pigs 
against the recombinant full-length Dube3a. In w1118 controls, one band 
corresponding to the size of the putative Dube3a protein (~107 kD) was 
detected. In contrast, no band was detected in the dube3a8O 
homozygous sample, which is expected to make no Dube3a protein. 
This result also confirmed the specificity of the anti-Dube3a antisera, 
generated against full-length Dube3a, in Western blot assays. The 
amounts of total proteins loaded on the gel from each sample are 
roughly the same according to tubulin controls. In the dube3a6J sample, 
no band was visible either (Figure 2.6). 
 
Two additional dube3a alleles were generated from an isogenized 
EP(3)3214 chromosome (Figure 2.5).  They are dube3a15B and 
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dube3a6PE (Figure 2.6). They were also characterized through DNA 
sequencing and Western blotting. dube3a6PE is a precise excision allele, 
with the EP insertion removed completely and no nucleotide deletion or 
insertion left behind.  Like dube3a8O and dube3a6J, dube3a15B is an 
imprecise excision allele bearing an ~1.2kb deletion, starting from the EP 
insertion site to the middle of dube3a exon3. Western blotting with 
polyclonal anti-Dube3a anti-sera showed no band in dube3a15B protein 
extracts and the amount of Dube3a in the dube3a6PE preparation is 
comparable to the w1118 controls (Figure 2.6).   
 
CONCLUSIONS 
Among the fourteen fly HECT domain proteins, CG6190 or 
dube3a, is clearly more similar to UBE3A in amino acid sequence than 
are the other thirteen (Figure 2.1, Table 2.1). The two protein sequences 
are conserved along the entire length of the proteins and the C-terminal 
HECT domain is more highly conserved. Unlike human UBE3A, which is 
subject to alternative splicing and has three N-terminal different isoforms, 
Dube3a is most likely encoded by one open reading frame and is 973 
amino acid long (Figure 2.1). 
  
By mobilizing an EP element in the 5’UTR of dube3a, four dube3a 





































Figure 2.5: Fly cross scheme for the generation of dube3a mutants by 
mobilizing the EP(3)3214 element inserted into the 5’-UTR of the dube3a 





















Figure 2.6: Wild-type and mutant dube3a alleles. (A) A diagram of the 
dube3a genomic region is shown at top (not to scale). There are ~400 bp 
between CG6700 and dube3a, and ~200 bp between CG6199 and 
dube3a. Boxes are exons; black indicates coding region and grey 
indicates non-coding regions. Four dube3a alleles generated by excision 
of EP(3)3214 are shown. The extents of the deletions in the mutant 
alleles are indicated. The four black bars beneath indicate the ~12.9 kb 
genomic DNA fragments in each of four transgenes. (B) Shown are blots 
of eye disc protein extracts from third instar larvae of the genotypes 
indicated. The blots were probed with guinea pig anti-Dube3a and anti-
tubulin as a loading control. 1X, 2X, and 4X indicate different amounts 
(7.5, 15 and 30ul respectively) of the same protein extract. For the blot 
on the right, in each lane, 35ul protein extracts from third instar larvae of 
the corresponding genotypes were loaded. 
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and Western blotting analyses. Two of them are likely null alleles and 
they are homozygous viable and fertile with no morphological defects 
that are obvious externally. As humans with Angelman syndrome as well 
as UBE3A knock-out mice are viable and more-or-less normal externally, 
the viable phenotype of these dube3a knock out mutants is consistent 
with the idea that Drosophila dube3a is the homolog of human UBE3A.  
 
These dube3a loss-of-function mutants will be analyzed to 
determine if they have mutant phenotypes suggestive of a neural 
function for dube3a and similar to those seen in UBE3A deficient people 
and mice (see Chapter 4). The results will determine if Drosophila 




Chapter 3: Dube3a Protein Expression Patterns 
and Subcellular Localizations 
 
INTRODUCTION 
Human UBE3A is transcribed in a variety of tissues and cell types, 
including the brain, heart, skeletal muscle, liver,  pancreas, kidney, lung, 
adrenal gland, intestine, placenta (Sutcliffe et al. 1997; Vu and Hoffman 
1997; Rougeulle and Lalande 1998), fibroblasts, lymphoblasts (Nakao et 
al. 1994), and foreskin keratinocytes (Huibregtse et al. 1993). UBE3A is 
also expressed in the brain (Rougeulle and Lalande 1998). While bi-
allelic expression of UBE3A was demonstrated in all other human 
tissues and cell types examined, in the brain, UBE3A is predominantly 
transcribed from the maternal allele (Rougeulle et al. 1997; Vu and 
Hoffman 1997).  
 
Transcripts of murine UBE3A were detected in extensive mouse 
brain sections, liver and testis (Albrecht et al. 1997; Sutcliffe et al. 1997). 
Unlike in other tissues or brain regions, in the murine hippocampus and 
the cerebellar Purkinje cell layer, the maternal copy of UBE3A is 
transcribed preferentially (Albrecht et al. 1997; Jiang et al. 1998; Miura et 
al. 2002). Analyses of the UBE3A expression pattern in embryonic mice 
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indicate that UBE3A is expressed broadly early in embryogenesis and 
later concentrates in neural tissue (Albrecht et al. 1997). 
 
Knowing the expression patterns and cell-type specificity of 
dube3a during fly development would shed light on its potential function. 
Most importantly, expression of dube3a in the fly nervous system will 
provide validation for the establishment of a fly AS model, which is 
based on the speculation that the mechanisms underlining the functions 
of fly UBE3A orthologs in the neuronal cells are conserved from fly to 
human. Particular attention would be paid to the expression of dube3a in 
the mushroom bodies (MB), the seat of learning and memory (Roman 
and Davis 2001; Heisenberg 2003). Whether endogenous dube3a, and 
most likely its substrate(s) as well, are expressed in fly tissues amenable 
to convenient and efficient genetic screens, such as the eye and the 
wing, will also test the feasibility of future modifier screens based on 
phenotypic abnormalities in these tissues.  
 
RESULTS AND DISCUSSION 
dube3a mRNA Expression Patterns 
As stated in Chapter 2, transcription of dube3a in fly embryos, 
larvae and adults were revealed by RT-PCR experiments. RT-PCR also 
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indicated that dube3a mRNA is present in larval eye discs, suggesting its 
substrate(s) may also present in this tissue.  
 
Dube3a Proteins Expression Patterns 
Means of protein expression pattern detection 
Anti-Dube3a polyclonal antisera 
Two different antisera (one in rat and one in Guinea pig) were 
generated against full-length Dube3a made in bacteria. Rat anti-Dube3a 
polyclonal antisera were used for tissue immunostaining whenever 
possible. The specificity of these antisera for immunostainings was 
tested by staining larval antenna-eye disc complex containing dube3a8O 
or dube3a6J homozygous clones. Labeling was observed in the wild-type 
areas but not the null clone areas (Figure 3.1).  When used for embryo 
immunostaining, Dube3a was absent in dube3a8O embryos while present 
in the wild-type embryos, which further confirmed the tissue specificity of 
anti-Dube3a (Figure 3.2). In addition, as described in Chapter 2, the 
specificity of these rat anti-Dube3a antisera was also verified on Western 
blots. The specificity of the guinea pig anti-Dube3a antibody was verified 
on Western blots as well, although it did not work for immunolocalization 





Figure 3.1: Dube3a expression in larval eye discs. Confocal immuno-
fluorescence images of third instar larval eye discs are shown. (A, A’) A 
dube3a8O homozygous clone surrounded by dube3a8O/dube3a+ cells is 
shown in a disc labeled with rat anti-Dube3a. Little or no Dube3a (red) is 
detected in the clone, indicating that the antibody is specific for Dube3a. 
Dube3a is ubiquitous and cytoplasmic in the eye disc outside the clone. 
Identical Dube3a expression patterns were observed with anti-Dube3a 
on wild-type eye discs (A, A’), with anti-GFP on eye discs containing a 
ggfp-dube3a transgene (Figure 2.4) that expresses GFP-Dube3a (B-B’’), 
and with anti-Myc on eye discs containing a g6myc-dube3a transgene 
(Figure 2.4) that expresses 6mDube3a (C-C’’). Dube3a appears to be 


























Figure 3.2:  Dube3a expression in embryos. Confocal immunofluorescence images are shown. (A-C”) 
dube3a+ embryos labeled with Dube3a (green) and Elav (red); A-A” are the same embryo; A shows 
Dube3a, A’ is a merge of Dube3a and Elav, and A” is an enlargement of part of A’ (Same for B-B” and 
C-C”). (D-F) dube3a8Oembryos; no Dube3a is detected.  
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 g6mdube3a and ggfpdube3a transgenes 
In addition to the anti-Dube3a antibodies, an alternative way to 
look at the expression pattern of Dube3a is to use flies carrying large 
genomic transgenes encoding either 6mDube3a (6×MycDube3a) or 
GFPDube3a and anti-Myc antibodies or anti-GFP antibodies. These 
6XMyc and GFP tag sequences were inserted in-frame into the 5’ ends 
of the dube3a open reading frames (Figure 2.6).  
 
Tissue expression patterns of the endogenous Dube3a protein  
Embryos 
During embryogenesis, Dube3a protein can be detected from 
stage 5 to later stages (earlier stages were not analyzed).  Ubiquitous 
distribution of Dube3a protein is observed, and its expression is detected 
in the embryonic nervous system, identified by double-labeling with anti-
Elav, which labels all neurons (Figure 3.2).  
 
Larval eye discs 
In larval eye-antenna discs, Dube3a protein has a ubiquitous 
distribution and does not display cell-type specificity (Figure 3.1).   
 

























Figure 3.3: 6mDube3a expression in embryos. Confocal immunofluorescence images are shown. (A-
D”) embryos containing a g6myc-dube3a transgene that expresses 6mDube3a are labeled with anti-
Myc (green) and anti-Elav (red); A-A” are the same embryo; A shows 6mDube3a, A’ shows Elav, and 
A” is a merge of 6mDube3a and Elav (Same for B-B”, C-C” and D-D”.) (E-H) w1118 embryos (without a 
g6myc-dube3a trans-gene); in contrast to Elav (red), no 6mDube3a is detected. The 6mDube3a 
expression patterns are identical to those of endogenous Dube3a (Figure 3.2). 
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Anti-Myc immunostainings of g6mdube3a embryos resembles 
anti-Dube3a w1118 embryo staining results. The anti-Myc staining 
patterns were absent in w1118 embryo controls (Figure 3.3).  
 
Larval eye discs 
Immunostainings of g6mdube3a larval eye discs with anti-Myc 
and immunostainings of ggfpdube3a larval eye discs with anti-GFP show 
comparable results to anti-Dube3a w1118 eye disc immunostaining 
(Figure 3.1).  
 
Larval central nervous system 
6mDube3a protein has a ubiquitous distribution in the larval 
central nervous system with pronounced expression in the neuroblasts 
and their immediate progeny. Very low levels of expression are observed 
in differentiated neuronal cells and glia. These observations were made 
by labeling the g6mdube3a larval brains with anti-Myc, and co-labeling 
either with anti-Elav, which labels all neuronal nuclei (Figure 3.4), or 
nuclear GFP (from UAS-nucGFP) driven by various neuronal Gal4 
drivers. For both l(3)31-1-Gal4 and Mz1060-Gal4, the GAL4 proteins 
were expressed in the neuroblasts and their immediate progeny (Figure 
3.5). Cha-Gal4 expresses GAL4 specifically in cholinergic neurons. OK6-
























Figure 3.4: 6mDube3a expression in larval central nervous system. Confocal immunofluorescence 
images are shown. In all rows, panels 4 and 5 are enlargements of the same regions of panels of 2 
and 3, respectively. (A-C) 6mDube3a (green) and Elav (red). (A1-A5) Apical view of ventral nerve 
cord. 6mDube3a is present in the Elav+ cells, and also in other cells. (B1-B5) Basal view of ventral 
nerve cord. 6mDube3a is present in neuroblast (NB) cytoplasm and in that of surrounding Elav+ 
progeny. (C1-C5) Larval brain is shown. 6mDube3a is present mainly in NBs and is also in 
























Figure 3.5: 6mDube3a expression in the neuroblasts of larval central nervous system. Confocal 
immunofluorescence images are shown. 6mDube3a (green) and Nuclear GFP (purple). Nuclear GFP is 
expressed from UAS-nucgfp driven by Mz1060-Gal4 (A’-A’’ and B) or l(3)31-Gal4 (C’-C’’, E’-E’’ and D). 
A’’ is a merge of A and A’ (Same for C” and E”). E-E’’ are enlargements of the same regions of panels 
C-C’’, respectively. Both Mz1060-Gal4 and l(3)31-Gal4 mark neuroblasts and neurons; 6mDube3a is 
present in these marked cells in larval CNSs containing a g6myc-dube3a transgene(A’-A’’ and C’-C’’), 
























Figure 3.6: Low levels of 6mDube3a in differentiated neurons and glial cells in larval central nervous 
system. Confocal immunofluorescence images of the apical view of ventral nerve cord are shown. In 
all rows, panels 4 and 5 are enlargements of the same regions of panels of 1 and 3, respectively.  
Dube3a (green) and Nuclear GFP (purple). Nuclear GFP (purple) is expressed from a Gal4 driver and 
UAS-nucgfp. Low level 6mDube3a are present in OK6-Gal4 marked motor neurons (A1-A5); cha-
Gal4 marked cholinergic neurons (B1-B5); repo-Gal4 marked glia (C1-C5). 
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specific GAL4 driver (Figure 3.6). Background signal from anti-Myc is 
insignificant in the central nervous system of w1118 larvae, which lacks 
the g6mdube3a transgene and serves as a negative control (Figure 3.5 
B, D as examples). 
 
Adult brain 
As in larval brains, 6mDube3a is expressed broadly in the adult 
brain as shown by co-labeling the g6mdube3a adult brain with anti-Myc 
and anti-Elav (Figure 3.7).  
 
In contrast with larval brains (not shown), 6mDube3a is expressed 
at particularly high levels in the adult mushroom bodies (MB), the 
Drosophila brain center for associative learning and memory. Such 
6mDube3a mushroom body expression patterns were confirmed by co-
labeling with OK201Y-Gal4>UAS-GFP or OK107-Gal4>UAS-GFP, 
where both OK201Y-Gal4 and OK107-Gal4 are mushroom body drivers 
(Figure 3.7).  
 
Subcellular localization of Dube3a, 6mDube3a 
The subcellular localizations of Dube3a, 6mDube3a and 
GFPDube3a were also observed in the above tissue stainings. All these 


























Figure 3.7: 6mDube3a expression in adult brains. Confocal immunofluorescence images are shown. 
(A-A”) Dube3a is expressed broadly in brain cell cytoplasm, as compared to Elav in all neural nuclei. 
(B-C”) Mushroom bodies (purple) are marked by nuclear GFP expressed by OK201Y>UAS-nucgfp. B 




In summary, similar to the expression of vertebrate UBE3A, 
Dube3a protein is mainly cytoplasmic (Huibregtse, personal 
communication), and is expressed broadly through out fly development. 
Expression of Dube3a or 6mDube3a (encoded by g6mdube3a genomic  
transgenes) is detected in the nervous system at the embryo, larval and 
adult stages. In the adult brain, high levels of Dube3a are present in the 
adult mushroom bodies. As Angelman syndrome affects brain function, 
these results are consistent with the idea that Drosophila dube3a is the 
homolog of human UBE3A.  
 
The expression of Dube3a in the developing eye (larval eye disc), 
also suggest that the substrates of Dube3a may be present in this tissue. 
Thus, the overexpression eye phenotype described in Chapter 5 might 





Chapter 4: dube3a Mutant Flies Have Locomotor Defects 
 
INTRODUCTION 
 As dube3a null mutants are homozygous viable, they can be 
assessed for neurological phenotypes resembling those of AS patients. 
The four clinical features that occur in all AS cases are developmental 
delay, movement or balance disorder, unique behaviors and speech 
impairment. Seizures and microcephaly  are also present in a large 
proportion of AS (Williams et al. 2006). 
 
Two established and commonly used assays for adult locomotor 
behaviors in flies are the flight test and the climbing test. In consideration 
of the large impact of genetic background on fly behavioral performance, 
wild-type (dube3a6PE) and dube3a mutant (dube3a15B) flies isogenic for 
the two major autosomes were analyzed in parallel. As motor 
coordination can be affected by age, wild-type and mutant flies of similar 
ages were compared over a range of ages. 
 
As Angelman patients also experience seizures, the dube3a 
mutant flies were tested in the bang sensitivity and heat shock assay for 
this tendency. In these assays, flies are examined for paralysis after 




In AS cases, the major brain components affected are the 
hippocampus and cerebellum, which are involved in learning and 
memory and motor coordination, respectively. The corresponding 
Drosophila brain centers are the mushroom bodies (Roman and Davis 
2001; Heisenberg 2003) and the central body complex (Strauss 2002). I 
thus examined if there are morphological abnormalities in these 
structures in dube3a knock-out mutants.  
 
RESULTS AND DISCUSSION 
The ability of dube3a flies to initiate flight was tested with a flight 
assay described (Benzer 1973; Palladino et al. 2002). In brief, flies were 
dumped through a glass funnel into a glass graduated cylinder with the 
inside surface coated by mineral oil. Strong fliers would start flight 
immediately at the opening of the funnel and strike to the side of the 
cylinder near the top. Weak fliers, on the other hand, would initiate flight 
later and land near the bottom. The flight tests were done on flies 3-4 
days old and 7-8 days old. Approximately 300 flies were tested for each 
genotype at each time point and the results were counted as described 
in Palladino et al. (2002). The overall flight abilities of dube3a mutant 
and control flies were analyzed with the student’s t-test. When tested at 
3-4 days old, dube3a15B flies initiate flight as robustly as dube3a6PE (wild-
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type).  At age 7-8 days, however, dube3a15B are weaker fliers compared 
to dube3a6PE. The flight impairment in dube3a mutants is small but 
statistically significant, and absolutely consistent in several repeated 
experiments (Figure 4.1). 
 
The locomotor activity of dube3a mutants was also tested in a 
climbing assay as described (Orso et al. 2005) with some modifications. 
The flies tested were collected one day after eclosion. Twenty adult flies 
were kept in food vials to age. Upon the day of testing, the flies were 
transferred into empty plastic vials  and gently tapped down to the 
bottom of the vials and the percentage of flies climbing up to the 3cm 
line in 3 seconds were recorded with a digital camera. The climbing tests 
were performed on files at day 3-4 and 8-9 after eclosion. For each 
genotype, ~300 flies were tested and the results were analyzed by the 
student’s t-test. When tested at either 3-4 days or 8-9 days old, 
dube3a15B flies were less able to climb in comparison to dube3a6PE 
controls (Figure 4.2). 
 
To determine if the climbing defects in dube3a15B mutants are due 
solely to disruption of dube3a function, or if effects on expression of the 







































Figure 4.1: Defective flight initiation in dube3a mutants. Results of flight 
tests on two populations of ~300 flies each of different ages are shown. 
Very similar results were obtained in two repeats of this experiment. (A) 
The percentage of flies at each of 10 possible landing heights is shown. 
(B) The results in A are presented in bar graph form. The error bars are 
standard error. Using the t-test, the difference in performance between 






phenotypes, I generated two transgenes, one with wild-type genomic 
DNA containing the dube3a gene (gdube3a+), and the other an identical 
genomic DNA fragment, except for a missense mutation in the codon for 
the critical catalytic cysteine residue in Dube3a (gdube3aC941A) (Figure 
2.6). Transformants were generated with each construct, and their 
genetic backgrounds were homogenized by rounds of backcrossing with 
dube3a15B.  
 
Homozygotes for dube3a15B carrying a single copy of either 
gdube3a+ or gdube3C941A were tested in the climbing assay, along with 
dube3a6PE  homozygous flies and dube3a15B homozygous flies. I found 
that the wild-type gdube3a+ transgene restores wild-type climbing ability 
to the dube3a15B mutant flies, whereas the mutant gdube3C941A trans-
gene has no rescuing activity (Figure 4.2).   
 
These results suggest that the climbing defect of dube3a15B is 
caused by disruption of dube3a function and that flies lacking dube3a+ 
activity have reduced motor control (Figure 4.2). Furthermore, the ability 
of the wild-type gdube3a+ transgene, but not the gdube3C941A mutant, to 
rescue the climbing phenotype in dube3a mutant flies suggest that the 
involvement of dube3a in locomotion control depends on the ubiquitin E3 






























Figure 4.2: Defective climbing ability in dube3a mutants. Results of 
climbing tests are shown. In all panels, the results are averages of 16-18 
different trials, each performed on separate populations of ~20 flies. 
Error bars are standard error calculated considering each trial as a 
single experiment. Statistical significance was determined using the t-
test. (A) At both ages tested, dube3a mutants perform worse than wild-
type flies (P<0.05). (B) At both ages tested, a gdube3a+ transgene 
(Figure 2.4) rescues the dube3a mutant climbing defect to wild-type 
(P<0.05), while a gdube3aC941A mutant transgene (Figure 2.4) 
provides no rescue activity (P>0.15).  
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Two tests to induce seizures were performed.  First, I performed a 
Bang sensitivity test (for response to mechanical stress) on wild-type 
and dube3a mutant flies at age 2-3 days or 7-8 days. Second, a heat 
shock assay (for response to temperature stress) was performed on 
wild-type and dube3a mutant flies at age 3-4 days or 8-9 days. Neither 
wild-type nor dube3a mutants showed any signs of paralysis in either 
assay. No incidence of seizure has been induced in dube3a null flies 
under mechanical or heat stresses. This is in line with the fact that 
seizure is not present in all AS cases (Williams et al. 2006). Actually, 
attempts to induce seizure in AS mouse models have yield discrepant 
results. While inducible seizure were shown in the UBE3A deficiency 
mouse model constructed by Jiang et al. (1998), it was absent in the 
UBE3A knockout mice generated by Miura et al. (2002). The reason for 
such differences observed is unclear. Possibly, different genetic 
backgrounds could have an effect on mouse behaviors (Miura et al. 
2002).  
 
The morphology of the adult brains of dube3a15B and the 
dube3a6PE flies was examined by staining with anti-Elav and anti-
Fasciclin II. Anti-Fasciclin labels the adult mushroom bodies and well as 
the ellipsoid body of the central complex. No obvious morphological 
differences were detected between wild-type and dube3a mutant flies 
 87
 
(not shown). This observation is consistent with those made in AS 
mouse models: no apparent morphological change in hippocampus and 
cerebellum, the mammalian brain regions related to learning and 
memory and locomotor coordination (Jiang et al. 1998; Miura et al. 2002). 
 
CONCLUSIONS 
Similar to Angelman syndrome patients and AS mouse models, 
dube3a knock-out flies display locomotor dysfunction, including reduced 
flight coordination and climbing ability. These results suggest that the 
functions of fly Dube3a and human UBE3A may be similar and loss of 
UBE3A homologs in flies or human results in locomotor defects. Thus, 




Chapter 5: Dube3a Overexpression Causes 
Morphological and Behavioral Phenotypes 
 
INTRODUCTION 
 For genes with redundant roles in fly development, or mutants 
with no apparent morphological phenotypes, like dube3a, study of some 
aspects of their functions is facilitated by overexpressing these genes 
and analysis of the overexpression mutant phenotypes. This can be 
achieved with the well-established binary UAS-Gal4 system (Brand and 
Perrimon 1993). A large collection of Gal4 drivers with different temporal 
and tissue specificities is accessible in the Drosophila research 
community. There are two purposes to my Dube3a overexpression 
experiments. First, I want to generate morphological phenotypes useful 
for structure/function analysis of the Dube3a protein. These flies will also 
be useful later in modifier screens designed to reveal Dube3a substrates. 
Second, I want to know how sensitive the nervous system is to changes 
in the level of Dube3a substrates. 
 
The fly tissues used most commonly for targeting UAS-transgene 
expression are the eye or the wing. The advantages of using these 
tissues are: (1) The ease of observing the severity of the phenotypes in 
these tissues in living flies under a stereo microscope; (2) The 
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dispensibility of these structures for fly viability and fertility. Even flies 
with no eyes or wings can be maintained and used in future analyses. (3) 
Efficient tissue specific Gal4 drivers are available for eye and wing 
expression. In addition to provide valuable hints for the function of the 
RNA or protein products encoded by the UAS-transgenes, these 
attractive features of eye/wing specific expression are highly treasured 
as starting points for  genetic modifier screens. Genetic and biochemical 
interactions between the gene of interest and the mutants isolated in 
such modifier screens can be further investigated in other tissues, such 
as the nervous system. One successful example is the isolation of the 
tumor suppressor lethal (2) giant larvae (dlgl) gene as a genetic 
suppressor of the dfxr gain of function rough eye phenotype. Genetic 
interaction and physical association between dlgl and dfxr in neural 
development was confirmed (Zarnescu et al. 2005). 
 
In addition, excessive expression of Dube3a in the nervous 
system might provide crucial hints about the in vivo function of Dube3a 
in the nervous system. This is of great significance as the long-term 
interest in establishing a Drosophila Angelman syndrome model is to 
promote the understanding of Dube3a/UBE3A function and their AS-




RESULTS AND DISCUSSION 
Ubiquitous overexpression of dube3a results in lethality  
 Ectopic overexpression of UAS-dube3a+ transgene under the 
tubulin-Gal4 driver causes lethality. tubulin-Gal4 enables the ubiquitous 
expression of the UAS-dube3a in all fly tissues and all developmental 
stages.  
 
dube3a overexpression leads to eye and wing abnormalities  
Flies carrying one copy of the eye-specific GMR-Gal4 driver and 
one copy of a UAS-dube3a+ transgene have rough external eyes. While 
no apparent defects are present in the developing photoreceptor clusters 
in the GMR-Gal4>UAS-dube3a+ larval eye discs, the adult retina is 
completely disorganized as shown in adult eye sections (Figure 5.1).  
 
Flies carrying one copy of the UAS-dube3a+ transgene and one 
copy of the wing-specific MS1096-Gal4 driver have curly wings (Figure 
5.1).  
 
 As position in the genome can influence transgene expression level, 
I tested five independent UAS-dube3a+ transformant lines and they all 
result in lethality with tubulin-Gal4, eye roughness under GMR-Gal4 and 































Figure 5.1: Morphological defects in flies that overexpress dube3a+ in 
the eye or wing. Shown are external eyes (A, B), tangential sections of 
adult retinas (C, D), and wings (E, F) of flies that are wild-type (A, C, E) 
or overexpress the UAS transgene indicated with the eye-specific Gal4 
driver (GMR-Gal4) or the wing-specific driver (MS1096-Gal4) (B, D, F). 
In flies with either the UAS or the Gal4 driver alone, eyes and wings are 
wild-type. (A, E) Eyes are irregular and wing tissue is curly. (B, F)  Eyes 
and wings are wild-type. (C, D) Wild-type retinas contain organized 
hexagonal facets, each with eight photoreceptors arranged in a 
trapezoid (C). Retinal morphology is severely disrupted by Dube3a+ 
over-expression (D). In flies that overexpress dube3aC941A, eyes and 
wings look wild-type.  
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dube3a overexpression defects require its potential E3 activity 
It was a common concern that ectopic overexpression of a 
transgene might lead to non-specific phenotypes. To assess if the 
dube3a+ overexpression phenotypes are relevant to the physiological 
function of Dube3a, a UAS-dube3aC941A transgene, encoding a mutant 
protein Dube3aC941A, was generated and tested for its ability to elicit 
corresponding mutant defects. In Dube3aC941A, the essential cysteine941 
residue in the HECT domain (Figure 2.1), where the ubiquitin moiety 
passed down from the upstream E2s conjugates to the HECT E3s, is 
replaced by an alanine residue. For human UBE3A/E6AP, substitution of 
the equivalent cysteine820 to alanine abolishes the capability of E6AP to 
form a thiolester bond with ubiquitin (Huibregtse et al. 1995; Talis et al. 
1998). I found that Dube3aC941A behaves in flies like a loss-of-function 
mutant form of Dube3a+. Overexpression of Dube3aC941A (from either of 
two transformant lines) in the eye or the wing does not obviously affect 
their morphology. Likewise, ubiquitous expression of Dube3aC941A does 
not kill the flies.   
 
Also, as mentioned later in Chapter 6, overexpression of N-
terminally 3xmyc-tagged versions of Dube3a+ and Dube3aC941A results in 
phenotypes (Figure 6.2) identical to those with their untagged 
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counterparts, when the expression level of 3mDube3a proteins are 
comparable. 
 
These results suggest that the dube3a overexpression 
phenotypes are not artificial but depend on Dube3a’s potential E3 
function.  
 
Excessive Dube3a activity in the nervous system results in 
abnormal behaviors 
Overexpression of UAS-dube3a+ in the developing and adult 
nervous system under the control of the pan-neural Elav-Gal4 driver 
leads to deficiencies in movement coordination in adult flies. This 
movement defect was quantified using the climbing assay.   
 
In one experiment (Figure 5.2 A), the climbing ability of flies 
harboring the Gal4 driver transgene only, the UAS-dube3a+ transgene 
only, or flies with both transgenes that thus express high levels of 
Dube3a+ were compared. As in Figure 5.2 A, flies overexpressing 
Dube3a+ have reduced climbing ability, and that the defect is more 




In order to determine if the mutant phenotype caused by Dube3a 
overexpression is due to the catalytic activity of the protein rather than to 
a non-specific effect, the climbing activity of flies that overexpress 
Dube3aC941A, and flies that overexpress wild-type Dube3a from either of 
two different UAS-dube3a insertions were assayed. At all ages tested, 
each wild-type Dube3a overexpresser performs less well than the 
Dube3aC941A overexpresser (Figure 5.2 B). In addition, the climbing 
ability of flies overexpressing Dube3aC941A is similar to that of flies that 
express Gal4 alone.  
 
Thus, neural overexpression of Dube3a, but not Dube3aC941A, 
impairs climbing. This suggests that in the nervous system, Dube3a 
overactivity, presumably through over-ubiquitination of its substrates, is 
detrimental.  
 
 As both lack of Dube3a activity or excess Dube3a activity in the 
nervous system lead to similar, not opposite, neurological defects, I 
speculated that the fly nervous system is sensitive to the level of the 
substrate(s) of Dube3a. It is also possible that the subcellular 
accumulation of the substrate(s) (due to failure in being ubiquitinated 
and degraded) and the decreased levels of the substrate(s) (due to 






























Figure 5.2: Defective climbing ability in flies that overexpress dube3a+ in 
the nervous system. Results of climbing tests are shown. In all panels, 
the results are averages of 16-18 different trials, each performed on 
separate populations of ~20 flies. Error bars are standard error 
calculated considering each trial as a single experiment. Statistical 
significance was determined using the t-test. (A) At all ages tested, 
overexpression of dube3a+ in the nervous system results in climbing 
defects (P<0.01 for Gal4 alone vs. Gal4+UAS). The smaller effect of 
UAS alone on climbing is likely due to its expression without the Gal4 
driver. (B) At all ages tested, overexpression of dube3a+ as in A from 
either one of two transgenes decreases climbing ability from wild-type 
levels, while overexpression of dube3aC941A has no effect (P<0.01 for 




events in the neurons, but both result in similar gross neurological 
abnormality, such as climbing defects observed in the flies. 
 
CONCLUSIONS 
We have shown that overexpression of UAS-dube3a in the eye, 
the wing or ubiquitously, leads to severe morphological malformations, 
or lethality, respectively. Furthermore, extra Dube3a activity in the 
nervous system impairs climbing. All these overexpression defects 
depend on the presence of the critical catalytic cysteine in the HECT 
domain. These experiments implicate that like human UBE3A, fly 
Dube3a behaves as a HECT E3 ligase and its activity relies on the 
crucial cysteine residue in the HECT domain.  
 
These gain-of-function mutant phenotypes provide invaluable 
tools for further study of dube3a and UBE3A. For example, I can now 
test how Angelman syndrome-associated dube3a mutants behave in the 
overexpression assay (see Chapter 5). Also, I could ask if wild-type and 
mutant UBE3A lead to defects similar to dube3a when overexpressed in 
Drosophila (see Chapter 6).  
 
In addition, these gain-of-function mutant phenotypes are of great 
potential to be used as the background for genetic screens for 
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identification of Dube3a substrates and other genes in the pathway. 
However, as it is not clear that if Dube3a maintains its substrate 
specificity under the overexpression states, the candidate genes isolated 
in such screen needs to be analyzed in the dube3a loss-of-mutants to 
test if they are physiological substrate of Dube3a (and UBE3A) relevant 
to AS (also see Chapter 8).  
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Chapter 6: Overexpression of dube3a Carrying 
Angelman Syndrome Mutations 
 
INTRODUCTION 
Among the known AS-associated human UBE3A mutations, 
which are mostly frameshifts and nonsense mutations, there are eight 
missense point mutations, seven of which occur at amino acid residues 
conserved between Dube3a and UBE3A/E6AP. They are UBE3AC21Y, 
UBE3AI130T, UBE3AS349P, UBE3AL502P, UBE3AR506C, UBE3AE550L and 
UBE3AI804K (Figure 2.1). If corresponding mutations impair fly dube3a 
function, this would provide further evidence for conservation of function 
between human UBE3A and the fly Dube3a ortholog. The dube3a 
overexpression phenotypes dependent on its potential E3 function 
provide an in vivo assay for evaluating whether Dube3a missense 
mutant proteins are functional. 
 
RESULTS AND DISCUSSION 
Four dube3a transgenes encoding AS-associated Dube3a 
mutants were generated, namely, UAS-3mdube3aC55Y(corresponding to 
human UBE3AC21Y), UAS-3mdube3aT447P(corresponding to UBE3AS349P), 
UAS-3mdube3aR626C(corresponding to UBE3AR506C), and UAS-
3mdube3aI925K(corresponding to UBE3AI804K). All these UAS-transgenes 
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were 3×myc-tagged at their N-termini to facilitate further expression level 
analyses on Western blots.  
 
Whether the presence of the 3×Myc tag affects Dube3a protein 
function was first tested with UAS-3mdube3a+ and UAS-3mdube3aC941A 
controls. These two 3×myc-tagged transgenes behave the same as 
UAS-dube3a+ and UAS-dube3aC941A respectively. When driven by 
tubulin-Gal4, GMR-Gal4 or MS1096-Gal4, the UAS-3mdube3a+ 
transgene leads to lethality, eye roughness and curly wings, and the 
UAS-3mdube3aC941A transgene causes no mutant phenotypes (Figure 
6.1, Figure 6.2). Comparable expression levels of 3mDube3a+ and 
3mDube3aC941A proteins were detected on Western blots with GMR-
Gal4>UAS-3mdube3a larval eye disc extracts (Figure 6.2).  
 
For each of the four UAS-3mdube3a transgenes encoding AS-
associated missense alleles, at least three unique transformant lines 
were tested to minimize the possibility of position effects on transgene 
expression levels. The protein expression levels of these transgenes 
were also assayed on anti-Myc Western blots with protein extracts 




None of the UAS-3mdube3a transgenes led to overexpression 
phenotypes when driven by GMR-Gal4 or tubulin-Gal4, except UAS-
3mdube3aT447P, which showed variable results (Figure 6.2). Four of six 
UAS-3mdube3aT447P transgenic lines, at least one of which expresses 
similar levels of 3mDube3aT447P protein to 3mDube3a+ and 
3mDube3aC941A, result in no phenotypes. However, the other two of the 
six UAS-3mdube3aT447P transgenic lines causes lethality when driven by 
tubulin-Gal4 and one of them leads to rough eyes when driven by GMR-
Gal4. Both 3mDube3aR626C and 3mDube3aI925K behave identically to the 
catalytically inactive 3mDube3aC941A protein in this overexpression assay; 
the mutant proteins accumulate to similar levels as wild-type protein, but 
do not cause mutant phenotypes (Figure 6.2). 3mDube3aC55Y also 
behaves like 3mDube3aC941A in that it fails to cause phenotypes, but its 
level of accumulation is lower than that of 3mDube3aC941A and 
3mDube3a+. 
 
In addition, the UAS-3mdube3a transgenic lines expressing 
comparable level of 3mDube3aT447P, 3mDube3aR626C and 3mDube3aI904K 
and the UAS-3mdube3aC55Y transgenic line with the highest 
3mDube3aI904K-expressing level were tested for their ability to induce the 





Figure 6.1: Morphological phenotypes of flies that overexpress different 
UAS-3mdube3a transgenes in the eye and wing. Shown are external eyes 
(A-G) and wings (H-N) of flies that are wild-type (A, H), or those carrying a 
copy of either GMR-Gal4 or  MS1096-Gal4 and a copy of one of the UAS-
3mdube3a transgenes: UAS-3mdube3aWT (B, I), UAS-3mdube3aC55Y(C, J), 
UAS-3mdube3aT447P (D, K), UAS-3mdube3aR626C (E, L), UAS-
3mdube3aI925K (F, M), or UAS-3mdube3aC941A (G, N). Eyes and wing 
abnormalities are only observed in 3mdube3a+ overexpression. The 
expression levels of these UAS-3mdube3a transgenes are demonstrated 
in Figure 6.2 (B) and the transformant lines used for each transgene are 































Figure 6.2: Angelman syndrome missense mutations are loss-of-function 
mutations in dube3a. (A) A tabulation of the phenotypes that result from 
expression of six different UAS-3mdube3a transgenes in the eye (GMR-
Gal4), wing (MS1096-Gal4), or ubiquitously (tubulin-Gal4). The 
“mutation” column indicates which missense mutation is present in the 
fly gene (human isoform1 counterpart in parentheses). The “lines” 
column indicates independent transformant lines assayed. The “eye”, 
“wing”, and “ubiquitous” columns indicate whether or not expression 
resulted in a mutant phenotype. Shaded rows indicate lines that resulted 
in no phenotypes. The “blot” column indicates the transformant lines with 
their protein expression level displayed in the blot in (B) and their 
overexpression phenotypes displayed in Figure 6.1. (B) A blot of eye 
disc protein extracts from flies with no transgene (none), or flies with a 
GMR-Gal4 and a UAS line expressing wild-type 3mDube3a (wt), or one 
of the five missense mutant 3mDube3a proteins indicated. The blot was 
probed with guinea pig anti-Dube3a, so that endogenous protein serves 
as an internal loading control. 
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Gal4 and tubulin-Gal4 results, no curly wing defects were observed in 
these flies (Figure 6.1).  
 
In vitro biochemical properties of the human UBE3A counterparts 
to Dube3aI925K (UBE3AI804K), Dube3aC55Y (UBE3AC21Y), and Dube3aT447P 
(UBE3AS349P) have been studied (Cooper et al. 2004). Unlike 
Dube3aI925K, which is apparently stable in flies, UBE3AI804K is an 
unstable protein in vitro.  Dube3aC55Y, however, is cannot be 
overexpressed to a high level, suggesting that it might be an unstable 
protein in flies.  Its human counterpart UBE3AC21Y is also unstable in 
vitro. Finally, while Dube3aT447P is partially active in flies, in vitro 
UBE3AS349P cannot ubiquitinate the substrate HHR23A. Perhaps this 
difference in the fly and in vitro assays is because the assays measure 
Ub ligase activity on different substrates.  
 
CONCLUSIONS 
In summary, the fly counterparts of the four AS missense alleles 
tested behave as loss of function mutations in the fly. This is supportive 
of the idea that dube3a and UBE3A are functional homologs and that AS 





Chapter 7: Expression of Human UBE3A in Drosophila 
 
INTRODUCTION 
As overexpression of wild-type fly Dube3a leads to mutant 
phenotypes, the possibility of inducing similar defects through 
overexpressing human UBE3A was examined. There are three human 
UBE3A isoforms that differ at their N-termini resulting from alternative 
splicing. They are 875aa long isoform 2, 872aa long isoform 3, and the 
853aa long isoform1 (Figure 2.1). It is not known whether any one of the 
isoforms predominates in the human brain (especially in the 
hippocampus and the Purkinje cells). Whether the subtly different N-
termini are functionally significant is also unclear.  
 
RESULTS AND DISCUSSION 
UAS-UBE3Aiso2+ and UAS-UBE3Aiso1+ transgenes were generated, 
encoding the wild-type UBE3A isoform2 and UBE3A isoform 1 proteins, 
respectively. When driven by GMR-Gal4 (eye), MS1096-Gal4 (wing) or 
tubulin-Gal4 (ubiquitous), none of these transgenes causes mutant 
phenotypes.  
 
To determine whether this was due to a failure to overexpress the 
UBE3A proteins, a 3Xmyc-tagged UAS-3mUBE3Aiso1+ transgene was 
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generated and two independent transformant lines were obtained. When 
expression of the UAS was driven with any of the three Gal4 drivers, 
these lines behaved identically to those expressing untagged UBE3A 
proteins: no mutant phenotypes resulted. By mobilizing the UAS 
insertion in these two lines, I generated 20 different lines with the UAS 
construct in different positions in the genome. When expressed using the 
ubiquitous Gal4 driver, only one line showed a lethal phenotype. Two 
more 3Xmyc-tagged UAS-3mUBE3A transgenes were made as well. 
They are UAS-3mUBE3Aiso1C21Y and UAS-3mUBE3Aiso1S347P. Protein 
extracts of several lines of these 3Xmyc-tagged transgenes were 
assayed on Western blots for the level of 3mUBE3A, and the protein 
levels were vanishingly low compared to the levels of 3mDube3a (Figure 
7.1). I have not determined why the human protein fails to accumulate 
appreciably in the fly. Nevertheless, I conclude that at least using the 




 Recently, Reiter et al. (2006) identified Drosophila Pebble (a 
guanine nucleotide exchange factor) as one of twenty proteins whose 
levels are increased when human UBE3A (isoform 2) is overexpressed 

































Figure 7.1: Human UBE3A proteins could not be overexpressed in 
Drosophila. (A) A tabulation of the phenotypes that result from ectopic 
expression of five different UAS transgenes encoding human UBE3A in 
the eye (GMR-Gal4), wing (MS1096-Gal4), or ubiquitously (tubulin-Gal4). 
The layout of the table is the same as the one in Figure 6.2 A. (B) A blot 
of eye disc protein extracts from flies with no transgene (w1118, negative 
control), or flies with a GMR-Gal4 and a UAS line expressing wild-type 
3mDube3a (positive control), or a UAS line encoding 3mUBE3A proteins 
as indicated. The blots were probed with mouse anti-Myc and anti-
tubulin, which serves as an internal loading control. The transgenic lines 
underlined in (A) are the ones used for this blot (L1, L2 or L3 for each 




were able to suppress Pebble overexpression phenotypes. The results 
of further experiments using the fly and mouse models suggest that the 
mouse Pebble homolog, ECT2 (epithelial cell transforming sequence 2), 
may be a direct target of UBE3A. At present, we cannot reconcile our 




Chapter 8: Overall Conclusions and Future Directions 
 
OVERALL CONCLUSIONS 
The data described here provide strong evidence for the idea that 
dube3a is the Drosophila homolog of human UBE3A and that dube3a 
mutants could serve as a fly model for Angelman syndrome. First, as the 
most likely fly homolog of human UBE3A, Drosophila dube3a is present 
in the fly nervous system at the embryonic, larval and adult stages and 
high level expression of Dube3a is present in the adult mushroom bodies, 
the brain components involved in associative learning and memory. 
Second, I have generated dube3a null mutants and they appear normal 
externally, but display abnormal locomotor behaviors. Third, 
overexpression of Dube3a causes morphological or behavioral 
phenotypes dependent on the HECT domain function. Finally, most of 
the missense mutations identified in Angelman syndrome patients are in 
amino acid residues conserved between the human UBE3A protein and 
Drosophila Dube3a protein. When four of such mutations were 
introduced into Dube3a, these mutants act as loss-of-function alleles.  
 
 The development of a Drosophila AS model will help to elucidate 
the underlying mechanism of AS pathogenesis, especially in identifying 
the substrates of dube3a and UBE3A relevant to AS. Unfortunately, the 
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unique imprinting feature of AS could not be studied in the fly model, as 
there is not similar CpG island-related imprinting in flies.   
 
FUTURE DIRECTIONS 
Genetic Screens to Identify dube3a Substrate(s) and Other Genes 
in the Pathway 
Genetic screens using the dube3a overexpression eye phenotype 
or wing phenotype can now be carried out to identify the substrate(s) of 
dube3a and possibly other genes involved in the same pathway. As the 
overexpression defects are dependent on the potential E3 function of 
Dube3a, a plausible explanation for these overexpression phenotypes is 
that overexpressing dube3a in the eye or the wing, where endogenous 
dube3a, and most likely its substrate(s) as well are present, results in 
excessive ubiquitination and then excessive degradation of these target 
protein by the proteasome. The decrease in the substrate levels 
interferes with certain processes in eye/wing development and results in 
rough eyes or curly wings. If this speculation is correct, then the 
substrates potentially could be isolated using genetic screens. For 
example, a loss-of-function mutation in a substrate gene would be 
expected to behave as a dominant enhancer of the eye or wing 
phenotype, while overexpression of the substrate gene would be 
expected to suppress the phenotypes. Mutations in genes that facilitate 
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the ubiquitin pathway or positively regulate dube3a expression or 
function could also be recovered in such genetic screens.  
  
 Various genetic screen strategies are available. Large scale EMS 
screens have the highest potential to identify most of the genes involved 
in the relevant molecular pathways and cellular processes. However, the 
follow-up mapping processes to identify the genes carrying EMS-
induced mutations could be rather intensive and usually rely on the 
mutants having a lethal or morphological phenotype on their own.  
 
The large collections of P-element (loss-of-function) or EP-
element (loss-of-function and gain-of-function) insertions and the 
isogenic deficiency kits could help to eliminate these drawbacks, 
although the EP-element and P-element lines do not cover as much the 
genome as a saturated EMS screen would. In addition to providing loss-
of-function mutants as the P-element or deficiency collections, the EP 
stocks can be used for analyzing gain-of-function phenotypes of 
adjacent genes simply by crossing into a Gal4 driver.  
  
 I think that the best choice for the first genetic screen would be 
the isogenic deficiencies. Isogenic P-elements could be used to find 
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genes within the deficiencies. In parallel, the EP collections could be 
used for a screen for gain-of-function modifiers.  
 
Testing If UBE3A Substrates Identified So Far Are Dube3a 
Substrates in the Nervous System 
Another great advantage to the fly model is that the potential 
relevance of a Dube3a substrate to AS may be tested easily through a 
variety of genetic and biochemical experiments.  
 
Overexpression in the brain of Dube3a substrates relevant to AS 
should phenocopy the motor dysfunction observed in dube3a loss-of-
function mutations. This powerful assay may be used immediately to test 
whether the UBE3A substrates already identified biochemically (the Src 
family tyrosine kinase Blk, the excision repair protein HHR23, the 
replication licensing factor Mcm7 and Pebble/ECT2) are relevant to AS.  
 
We can also examine if the loss-of-function mutations in these 
candidate Dube3a substrates enhance the Dube3a overexpression eye 
or wing defects. Conversely, overexpression of these substrates 
simultaneously with Dube3a may alleviate the eye or wing malformations 




Whether the cellular concentration of the substrate is altered in 
dube3a null or overexpressing flies can be assesses both in vivo and in 
vitro, if antibodies are available. Additionally, whether the substrate is 
ubiquitinated in the presence or absence of Dube3a can be analyzed on 
Western blots.  
  
 Ultimately, the mouse homologs of promising potential substrates 








Drosophila stocks generated for this project 
w; dube3a6PE / TM6B                                         
w; dube3a15B / TM6B                                         
w; dube3a6J / TM6B                                          
w; dube3a8O / TM6B                                         
w; gdube3a+ / CyO; dube3a15B / TM6B              
w; gdube3aC941A / CyO; dube3a15B / TM6B         
 
w; ggfpube3aL2 / TM6B                                 
w; ggfpdube3aL3 / TM6B                                  
 
w; g6mdube3aL2 / CyO                                     
w; g6mdube3aL3/ TM6B                                  
w; g6mdube3aL2; g6mdube3aL3, nucGFP / TM6B  
 
w; UASt-dube3a+L1 / CyO                                              
w; UASt-dube3a+L2 / TM6B                                              
w; UASt-dube3a+L3 / TM6B                                             
w; UASt-dube3a+L6 / TM6B                                              
w; UASt-dube3a+L 8/ CyO                                                                                         
 
w; UASt-dube3aC941AL1 / TM6B   
w; UASt-dube3aC941AL2 / TM6B   
 
w; UASt-3mdube3a+L1 (on 2nd) 
w; UASt-3mdube3a+L2 / TM6B 
w; UASt-3mdube3a+L3 / TM6B 
w; UASt-3mdube3a+L4 / TM6B 
 
w; UASt-3mdube3aC55YL1 / CyO 
w; UASt-3mdube3aC55YL2 / TM6B 
w; Sco / CyO; UASt-3mdube3aC55YL3 / TM6B 
w; Sco / CyO; UASt-3mdube3aC55YL4/ TM6B 
w; UASt-3mdube3aC55YL5/ CyO; MKRS / TM6B 
w; UASt-3mdube3aC55YL6 / CyO; MKRS / TM6B 
w; UASt-3mdube3aC55YL7 / CyO; MKRS / TM6B 




w; UASt-3mdube3aT447PL1 / TM6B 
w; UASt-3mdube3aT447PL2 / CyO; MKRS / TM6B 
w; UASt-3mdube3aT447PL3 / CyO; MKRS / TM6B 
w; UASt-3mdube3aT447PL4 / CyO; MKRS / TM6B 
w; UASt-3mdube3aT447PL5 / CyO; MKRS / TM6B 
w; UASt-3mdube3aT447PL6 / CyO; MKRS / TM6B 
 
w; UASt-3mdube3aR626CL1 (on 2nd) 
w; UASt-3mdube3aR626CL2 / CyO 
w; UASt-3mdube3aR626CL3 / TM6B 
w; UASt-3mdube3aR626CL4 / TM6B 
w; UASt-3mdube3aR626CL5 / TM6B 
w; UASt-3mdube3aR626CL6 / TM6B 
w; UASt-3mdube3aR626CL7 / TM6B 
w; UASt-3mdube3aR626CL8 / TM6B 
  
w; UASt-3mdube3aI925KL2 / CyO; MKRS / TM6B 
w; UASt-3mdube3aI925KL3 / CyO; MKRS / TM6B 
w; UASt-3mdube3aI925KL4 / CyO; MKRS / TM6B 
w; UASt-3mdube3aI925KL5 / TM6B 
w; UASt-3mdube3aI925KL6 / TM6B 
w; UASt-3mdube3aI925KL7 / CyO; MKRS / TM6B 
w; UASt-3mdube3aI925KL8 / TM6B 
 
w, UASt-3mdube3aC941AL1 (on X-ch) 
w; UASt-3mdube3aC941AL2 / CyO 
w; UASt-3mdube3aC941AL3 / TM6B 
  
w; UASt-UBE3Aiso2+L1 / CyO 
w; UASt-UBE3Aiso2+L2 / TM6B 
w; UASt-UBE3Aiso2+L3 / TM6B 
 
w; UASt-UBE3Aiso1+L1 / TM6B 
w; UASt-UBE3Aiso1+L2 (on 2nd) 
w; UASt-UBE3Aiso1+L3 (on 2nd) 
 
w; UASt-3mUBE3Aiso1+L1 (on X-ch) 
w; UASt-3mUBE3Aiso1+L2 (on 2nd) 
 
w; UASt-3mUBE3Aiso1C21Y (on 2nd) 
 
w; UASt-3mUBE3Aiso1S349PL1 (on 2nd) 
w; UASt-3mUBE3Aiso1S349PL2 / TM6B 
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w; UASt-3mUBE3Aiso1S349PL3 / TM6B 
 
Stocks obtained from Bloomington stock center or other resources 
w; dube3aEP(3)3214 / TM6B                                              
w; Cha-GAL4.7.4 / CyO, sevRas1                                 
w; repo-Gal4 / TM3, Sb                                                  
w; OK6-Gal4                                                             (from Dr. Bing Zhang)                         
w; OK107-Gal4                                                                 
w; OK201Y-Gal4 
MZ1060-Gal4; sbbe(2)03432 / CyO                      (from Dr. Marla Sokolowski)             
sbbe(2)03432 / CyO-GFP; l(3)31-Gal4 / TM6C    (from Dr. Marla Sokolowski) 
 




w; GMR-Gal4  
w, MS1096-Gal4                                                    
yw; tubulin-Gal4/ TM3  
w; Elav-Gal4 (on 3rd)  
w; UAS-nucGFP8       
Sp/ CyO; TM6, Ubx / Sb∆2-3                                                       
TM2∆2-3 / MKRS∆2-3                                                                  
w; Sb/TM6B  
w; Sco/CyO; MKRS/TM6B  
 
Molecular Biology. All oligonucleotides were from Integrated DNA 
Technologies (Coralville, IA). PCR was performed using PCR Supermix 
(Invitrogen Corporation, Carlsbad, CA). DNA sequences of all PCR 
products were determined, and automated fluorimetric methods were 
used (ICMB DNA facility, UT Austin). Genomic DNA isolation was as 
described (Hamilton and Zinn, 1994). 
 
Confirmation of EP(3)3214 insertion site by PCR 
PCR was done with genomic DNA isolated from EP(3)3214 
homozygotes as the template and the primer pairs: 5'- TCCAGATAGTA 
GTTGAAGGGCGTC-3'/5’-CTTGCCGACGGGACCACCTTATGTTATT-3’ 
and 5'-GCCGCCCCTTTCTTTGTTTG-3'/ 5’-CACCCAAGGCTCTGCTC 
CCACAAT-3’. The PCR products were sequence and the sequences 
were then aligned with dube3a genomic DNA sequences using 




Analysis of dube3a mRNA through RT-PCR experiments 
dube3a RNA was isolated from desired fly tissues (embryos, larvae, 
adults or larval eye discs) with TRI reagent Kit (Molecular Research 
Center, Inc. Cincinnati, OH) according to the user manual. Reverse 
transcription was done with SuperScript II (Invitrogen) according to the 
manufacture manual. The cDNA was then used as the PCR templates. 
The primer pair 5'-GGATCCCAAACAAAGAAAGGGGCGGC-3'/5'-TGAC 
GGCGTGAGGATAAAGG-3' was used to amplify the 1.7kb 5’ dube3a 
RNA sequence. The primer pair 5'-CGGAAACCACTGATACCACTTGA 
G-3'/ 5'-GGATCCTGGTGGTATCAGTTCCAGATGACAG-3' was used to 
amplify the 1.4kb 3’ dube3a RNA sequence.  
 
P element mobilization to generate dube3a mutants  
dube3a8O and dube3a6J attempt: by mobilizing the EP(3)3124 element 
with ∆2-3 transposases (see Figure 2.4 for the cross scheme), ~250 
individual hop-out lines were generated. Lines that contained 
homozygous sub-viable or lethal hop-out chromosomes were discarded, 
and the remaining 135 lines were divided into 7 pools. Genomic DNA 
prepared from each pool (2 homozygous flies from each of the 20-25 
lines was used) was used as a template for PCR using the primers listed 
below. The PCR products were electrophoresed and analyzed for the 
presence of a smaller product indicative of a deletion. Continuation of 
the process with subpools led to the identification of the single lines 8O 
and 6J. The precise deletion endpoints in 8O and 6J were identified 
through DNA sequence determination of the PCR products. Primers 
used for such group PCR include: Forward primers: F1: 5'-
TCCAGATAGTAGTTGAAGGGCGTC-3' (~750bp upstream of the EP 
insertion site) and F2: 5'-GGCGATTTGGGACTTTGGT-3' (1550bp 
upstream of the EP insertion site), and Reverse primers: RA: 5'-
TGACGGCGTGAGGATAAAGG-3'; RB: 5'-CATCACCGAAAACATCGC-
3'; RC: 5'-GGATCCTGGTGGTATCAGTTCCAGATGACAG -3'; RD: 5'-
GGGCTAAAGAAGGGAAACA-3'; and RE: 5'-CCCGCAAGAAACTCAGA 
AACG-3'. PCR from wild-type fly genomic DNA with the primer pair 
F1/RA results in the amplification of a 3.1kb fragment; with the primer 
pair F1/RD results in the amplification of a 4.8kb fragment; with the 
primer pair F2/RA results in the amplification of a 3.9kb fragment; with 
the primer pair F2/RB results in the amplification of a 4.8kb fragment; 
with the primer pair F2/RC results in the amplification of a 5.3kb 
fragment; with the primer pair F2/Re results in the amplification of a 
6.0kb fragment. dube3a6PE and dube3a15B attempt: The isogenic precise 
(dube3a6PE) and imprecise (dube3a15B) excision chromosomes were 
generated with the cross scheme listed in Figure 2.5. Eye disc protein 
extracts of homozygotes each of the 120 independent lines were 
analyzed by Western blotting using guinea pig anti-Dube3a. Genomic 
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DNA of lines that appeared to express no Dube3a protein were analyzed 
as described above.  
 
Transgene construction and transformation. P element transfor-
mation of w1118 flies was performed using standard techniques. 
pUASt-dube3a+ 
The 1.7kb dube3a 5’ cDNA fragment and a 1.4kb dube3a 3’ cDNA 
fragment were obtained as described above, through RT-PCR with w1118 
adult fly samples. These PCR products were ligated into pGEMTe vector 
(pGEMTe, Promega Corporation, Madison, WI) to generate pGEMT-
dube3a5’ and pGEMT-dube3a3’ respectively. These cloned fragments 
were confirmed through sequencing. The 1.7kb 5’ fragment and the 
1.4kb 3’ fragments were then isolated as 1.7kb NotI/DraIII and 1.4kb 
DraIII/BamHI fragments and subcloned together into the NotI/BamHI-
digested pBSAscI vector (Chen and Fischer 2000) to generate pBSA-
dube3ae+. The 3.1kb dube3a cDNA fragment was then isolated from 
pBSA-dube3ae+ as a NotI/KpnI fragment and ligated into NotI/KpnI-




A 1.3kb dube3a coding fragment carrying a Cys941Ala substitution was 
obtained through PCR-mediated mutagenesis using pGEMT-dube3a3’ as 
the PCR template and the primer pair 5'-CGGAAACCACTGATACCACT 
TGAG-3'/ 5'-GAACGTTGAAGGCGGTGTGCGAGGTAGGCAA-3’, thus 
introduces an Ala codon at the place of the 941Cys codon. The 1.3kb 
Cys941Ala PCR fragment was ligated into pGEMTe vector and the 
presence of the 941Ala codon was confirmed by sequencing. The 1.3kb 
Cys941Ala fragment was then recovered as a NotI/AclI fragment and 
subcloned into the NotI/BamHI-digested pBSAscI vector, together with a 
0.1kb AclI/BamHI fragment isolated from pGEMT-dube3a3’, to generate 
a 1.4kb Cys941Ala dube3a 3’ cDNA fragment. The product is pBSA-
dube3a3’C941A. Isolated from pBSA-dube3a3’C941A as a DraIII/BamHI 
fragment, this 1.4kb Cys941Ala fragment was then pieced together with 
the 1.7kb NotI/DraIII dube3a 5’ fragment isolated from pGEMT-dube3a5’, 
into NotI/BamHI-digested pBSAscI vector to make pBSA-dube3aeC941A. 
The 3.1kb dube3a Cys941Ala fragment was then subcloned as a 




dube3a N-terminal coding fragment was obtained by PCR amplification 




T-3', which then ligated into pGEMTe vector and sequenced. The 
product is pGEMT-dube3aN’. A 1.2kb BamHI/AscI fragment was cut out 
pGEMT-dube3aN’ and pieced together with a 1.8kb AscI/BamHI fragment 
from pBSA-dube3ae+ into BamHI-digested p8036 vector (Harris and 
Macdonald 2001), from which the 3.0kb full-length dube3a coding 
sequence was recovered as a single BamHI fragment and inserted into 
the BamHI site of pBSAscI vector to make pBSA-dube3a+. A 1.8kb AscI 
fragment was then isolated from pBSA-dube3a+ and inserted into the 
AscI site of pUASt-3mdube3a5’ to make pUASt-3mdube3a+. pUASt-
3mdube3a5’ was constructed as following: a BglII site was introduced to 
replace Dube3a codon5-6 in pGEMT-dube3a5’ by PCR-based muta-
genesis using QuickChange Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA), with the primers 5’-AAGATGAACGGTGGCAGATCTGGC 
GAGGATGATCAG-3’/ 5’-CTGATCATCCTCGCCAGATCTGCCACCGTT 
CATCTT-3’ to generate pGEMT-B2-dube3a5’, which was then restricted 
with BglII/HindIII to accommodate a  0.1kb BamHI/3×myc fragment from 
pSPBP4-tsl-3×myc (Stevens L and Stein D, unpublished data) and a 
1.0kb BamHI/HindIII fragment from pBSA-dube3a+ together thus 
generating pGEMT-3mdube3a5’. Finally, a 1.8kb NotI fragment encoding 
the N-terminal part of Dube3a with a 3×myc tag fused in-frame was 
isolated from pGEMT-3mdube3a5’ and inserted into the NotI site of 
pUAStAscI to generate pUASt-3mdube3a5’.  
 
pUASt-3mdube3aC55Y 
A 0.2kb PCR fragment containing the beginning of dube3a coding 
sequence was amplified from pGEMT-dube3aN’ with the primer pair 5’-
CAGATCTCAGGATCCATGAACGGTGGCGGGGGT-3’/ 5’CAATTGGCA 
TTGCTGCAGTTGGCGTTCCCGTAGCCGGATTGTAGTTG-3’, thus 
introducing a Tyr codon at the place of the 55Cys codon. This PCR 
fragment was ligated into pGEMTe vector and sequenced. The 0.2kb 
sequence was then recovered as a SacI/MfeI fragment and subcloned 
together with a 2.9kb MfeI/XhoI fragment cut out of pBSA-dube3a+ into 
the SacI/XhoI-digested pBSAscI vector to generate pBSA-dube3aC55Y. 
The 3.1kb dube3aC55Y was then recovered from pBSA-dube3aC55Y as a 
BamHI fragment and ligated into EcoRI/ BglII-digested pUAStAscI, 
together with a 0.2kb 3×myc EcoRI/BamHI fragment isolated from 
pUASt-UBE3Aiso1S349P described below.  
 
pUASt-3mdube3aT447P 
A 0.9kb dube3a coding fragment containing a Thr447Pro substitution 
was obtained by PCR with pBSA-dube3ae+ as the template and the 
primer pair 5'-ATCTTACCCAGAGTGTGCCGCAAC-3'/ 5’-GAAGACAAT 
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CTTTAAAACTTTGGGGACACTGATTATGGATTC-3’, which introduces 
a Thr codon at the place of the 447Pro codon. It was ligated into 
pGEMTe vector and sequenced to confirm the presence of the 447Thr 
codon This T447P fragment was then isolated as a 0.6kb BbsI fragment 
and replaced the correspondent fragment in pBSA-dube3a+, thus 
generated pBSA-dube3aT447P. A 1.8kb AscI fragment was then isolated 
from pBSA-dube3aT447P and inserted into the AscI site of pUASt-
3mdube3a5’to make pUASt-3×myc•dube3aT447P. 
 
pUASt-3mdube3aR626C 
A 1.1kb dube3a coding fragment carrying a Arg626Cys substitution was 
obtained by PCR with pBSA-dube3ae+ as the template and the primer 
pair 5’-CTTAAGCTGACGGTGCGATGCGACCAGCTCATCAACGAC-3’/ 
5'-GGATCCTGGTGGTATCAGTTCCAGATGACAG-3' introducing an Arg 
codon at the position of 626Cys, and ligated into pGEMTe vector and 
sequenced to verify the presence of the 626Arg codon. This R626C 
fragment was then recovered as a 0.9kb AflII/MluI fragment and 
replaced the correspondent fragment in pBSA-dube3a+, thus generated 
pBSA-dube3aR626C. A 1.8kb AscI fragment was then isolated from pBSA-




A 1.2kb fragment of dube3a coding sequence containing a Ile925Lys 
substitution was obtained by PCR with pBSA-dube3ae+ as the template 
and the primer pair 5'-CGGAAACCACTGATACCACTTGAG-3'/5’-ACGC 
GTCTTTAGCAGACGCAGGCATTTCAG-3’, which introduces an Ile 
codon at the position of the 925Lys codon, and ligated into pGEMTe 
vector. The fragment was then recovered as a 0.9kb AflII/MluI fragment 
and replaced the corresponding fragment in pBSA-dube3a+, thus 
generated the pBSA-dube3aI925K. A 1.8kb AscI fragment was then 
isolated from pBSA-dube3aI925K and inserted into the AscI site of pUASt-
3×myc•dube3a5’ to make pUASt-3mdube3aI925K. 
 
pUASt-3mdube3aC941A  
A 1.8kb fragment of dube3a coding sequence containing a Cys941Ala 
substitution was cut out of pBSA-dube3aeC941A and inserted into the AscI 
site of pUASt-3mdube3a5’ to make pUASt-3mdube3aC941A. 
 
All the UBE3A fragments used below were subcloned from various 





The 2.6kb BamHI/HindIII UBE3Aiso1+ fragment was converted into a 
BamHI/AscI fragment and linked into pUASpAscI vector, where an AscI 
site is inserted into the XbaI site of pUASp vector (Rorth 1998). The 
UBE3Aiso1+ fragment was then recovered from pUASp-UBE3Aiso1+ as a 
NotI/AscI fragment and inserted into pUAStAscI. 
 
pUASt-UBE3Aiso2+ 
The 2.6kb UBE3Aiso2+ cDNA fragment was converted into a NotI/AscI 
fragment as above and linked into pUAStAscI vector. 
 
pUASt-3mUBE3Aiso1+ 
A 0.2kb 3×myc BamHI fragment recovered from pGEMT-3mdube3a5’ 
was inserted into the BamHI site of pUASp-UBE3Aiso1+, from where the 




A 0.2kb 3×myc BamHI fragment recovered from pGEMT-3mdube3a5’ 
was pieced in-frame with a 2.6kb BamHI/NotI UBE3Aiso1C21Y into 
BglII/NotI-digested pUAStAscI vector  
 
pUASt-3mUBE3Aiso1S349P 
A 0.2kb 3×myc BamHI fragment recovered from pGEMT-3mdube3a5’ 
was pieced in-frame with a 2.6kb BamHI/NotI UBE3Aiso1S349P into 
BglII/NotI-digested pUAStAscI vector  
 
pCaspeR4-gdube3a+  
A 13kb XhoI/BamHI dube3a genomic DNA fragment was isolated from 
BAC clone BACR19G23 (BACPAC Resources, http://bacpac.chori.org) 
and ligated into XhoI/ BamHI-cut pBSAscI to generate pBSA-gdube3a+, 
from which the 13kb genomic fragment was subcloned into the 




A 0.25kb SphI fragment containing the constructed Cys941Ala substi-
tution was isolated from pUASt-dube3aC941A and replaced the corres-
ponding piece in pBSA-gdube3a+, thus generating pBSA-gdube3aC941A, 
from which the modified 13kb genomic fragment was subcloned into 





Similar to the construction of pGEMT-B2-dube3a5’ described in pUASt-
3mdube3a+, a pBSA-gB2-dube3aSA carrying a subcloned 1.8kb 
SpeI/AscI fragment from pBSA-gdube3a+ was generated with a BglII site 
engineered in replace of codon5-6. pBSA-gB2-dube3aSA was then 
restricted with BglII/AscI to accommodate BamHI/3xmyc fragments from 
pSPBP4-tsl•3×myc and a 1.4kb BamHI/AscI fragment amplified from 
pBSA-gdube3a+ to generate pBSA-g6mdube3a-SA, in which the 
presence of two tandem 3×myc fragments was determined. The1.9kb 
SpeI/AscI fragment from pBSA-g6mdube3a-SA was then recovered and 
replace the corresponding sequence in pBSA-gdube3a+ to generate 
pBSA-g6mdube3a, from which the 13kb g6mdube3a fragment was 




pCaspeR4-ggfpdube3a was generated following exactly the same steps 
described in pCaspeR4-g6mdube3a construction, except that a 0.75kb 
BamHI/GFP fragment was used in place of the BamHI/3xmyc fragment. 
The BamHI/GFP fragment is obtained through PCR from pUASg-
gfpdube3a (Kracklauer et al. 2007) with the primer pair 5’-GGATCCATG 
AGTAAAGGAGGAGAAC-3’/ 5’-CTGTTGGCCTCCGATGTGAA-3’. The 
PCR product was cloned into pGEMTe and recovered as a BamHI 
fragment after the GFP sequence was confirmed.   
 
Dube3a antibodies 
The 3.0kb full-length dube3a coding sequence as described in pUASt-
3mdube3a+ construction was inserted into the BamHI site of pET-28a 
vector (Novagen, Madison, WI).  Expression of the His•Dube3a 
recombinant protein was induced in E. coli Codon-Plus RIL cells 
(Stratagene, La Jolla, CA). The recombinant protein was purified with 
His•Bind Resin (Novagen) following the user protocol. The purified 
protein was then sent to Pocono Rabbit Farm& Laboratory Inc 




Western blottings were performed as described (Chen et al. 2002; 
Fischer et al. 2004). The primary antibodies were used at the following 
dilutions: rat or guinea pig anti-Dube3a 1:5000; mouse anti-tubulin E7 
(Developmental Studies Hybridoma Bank, Iowa city, IA) 1:100; mouse 
anti-Myc 9B11 (Cell Signaling Technologies, Danvers, MA) 1:5000. The 
secondary antibodies were used at the following dilutions: HRP-
conjugated anti-guinea pig 1: 50,000; HRP-conjugated anti-rat 1:5000; 





Embryo immunostaining was done as described (Jones and Macdonald 
2007). The primary antibodies were used at the following dilutions: rat 
anti-Dube3a 1:500 (preabsorbed against dube3a8O homozygous 
embryos); mouse anti-Elav 9F8A9 (DSHB) 1:40; mouse anti-Myc 9B11 
1:4000; rat anti-Elav 7E8A10 (DSHB) 1:25. Cross-absorbed secondary 
antibodies were used at the following dilutions: Alexa Fluro 488 goat 
anti-mouse 1:500, Alexa Fluro 647 goat anti-rat 1:500 (Molecular Probes, 
Eugene, OR). Stained embryos were mounted in VectaShield mounting 
medium (Vector Laboratories, Burlingame, CA). Images were acquired 
with a Leica SP2 AOBS confocal microscope or a Leica TCS-SP 
confocal microscope. 
 
Eye disc immunohistochemistry 
Third instar larval eye discs were prepared as described (Fischer-Vize et 
al. 1992; Chen et al. 2002). Images were acquired with a Leica TCS-SP 
confocal microscope. The antibodies were used as follows: rat anti- 
Dube3a 1:500; rabbit anti-GFP 1:1000 (kindly provided by Hui Li and Dr. 
Arturo DeLozanne, UT-Austin); mouse anti-Myc 9B11 1:1000; Cy5 goat 
anti-rat 1:200 (Jackson Immunoresearch, West Grove, PA); Alexa Fluro 
488 goat anti-mouse 1:200; Alexa Fluro 488 goat anti-rabbit 1:200; 
Phalloidin 568 1:10 (Molecular Probes). 
 
Larval and adult brain immunohistochemistry 
Adult or larval brains were dissected in PBS and fixed in 4% 
paraformaldehyde at room temperature for 50 minutes, incubated in 
primary antibodies overnight at 4°C. The secondary antibody incubation 
was done at room temperature for at least 2 hours. PBST washes were 
done between the fixation and primary, secondary antibody incubations. 
The fly tissues were mounted with VectaShield mounting medium. 
Images were acquired with a Leica SP2 AOBS confocal microscope or a 
Leica TCS-SP confocal microscope. The primary antibodies were used 
as follows: mouse anti-Myc 9B11 1:4000; rat anti-Elav 7E8A10 1:30; 
mouse anti-Fasciclin II 1:50. Cross-absorbed secondary antibodies were 
used at the following dilutions: Alexa Fluro 488 goat anti-mouse 1:600; 
Alexa Fluro 647 goat anti-mouse 1:600; Alexa Fluro 488 goat anti-rat 
1:600; Alexa Fluro 647 goat anti-rat 1:600 (Molecular Probes). 
 
Heat shock assay 
Heat shock assays were performed on dube3a15B and dube3a6PE flies at 
age 3-4 days and 8-9 days old. Appropriately aged flies were transferred 
into empty vials and heat shocked in 37C water bath for signs of 
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paralysis, every 5 minutes. The latest time point is 20 minutes. For each 
genotype, more than 120 flies were tested each time. 
 
Bang sensitivity assay 
Bang sensitivity assay was done with dube3a15B and dube3a6PE flies as 
described (Zhang et al. 2002) at age 2-3 or 7-8 days old . For either 
genotype, more than 120 flies were tested.  
 
Flight test 
The ability of dube3a flies to initiate flight was tested with a flight assay 
described (Benzer 1973; Palladino et al. 2002). In brief, flies were 
dumped through a glass funnel into a glass graduated cylinder with the 
inside surface coated by mineral oil. Strong fliers would start flight 
immediately at the opening of the funnel and strike to the side of the 
cylinder near the top. Weak fliers, on the other hand, would initiate flight 
later and land near the bottom. The flight tests were done on flies 3-4 
days old and 7-8 days old. Approximately 300 flies were tested for each 
genotype at each time point and the results were counted as described 
in Palladino et al. (2002). The overall flight abilities of dube3a mutant 
and control flies were analyzed with the student’s t-test. 
 
Climbing assay 
The locomotor activity of dube3a mutants was tested in a climbing assay 
as described (Orso et al. 2005) with some modifications. The flies tested 
were collected one day after eclosion. Twenty adult flies were kept in 
food vials to age. Upon the day of testing, the flies were transferred into 
empty plastic vials  and gently tapped down to the bottom of the vial and 
the percentage of flies climbing up to the 3cm line in 3 seconds were 
recorded with a digital camera. The climbing tests were performed on 
files at day 3-4 and 8-9 after eclosion. For each genotype, ~300 flies 
were tested and the results were analyzed by the student’s t-test. 
 
Analysis of eyes and wings. 
Analysis of adult eyes and wings were done as described (Cadavid et al. 
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